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      ABSTRACT 
 
In Chapter I is a general description of novel metal complexes which hydrolytically 
cleave peptides, proteins, DNA, and other biological molecules. These reagents are becoming the 
more important as potential therapeutic agents. A panel of ligands was investigated for 
coordination to ZrIV and other metals in groups 4, 5, and 6 to effect the greatest degree of 
hydrolysis. Chapter II describes a ZrIV complex which is capable of hydrolyzing a 30 amino acid 
peptide, insulin chain B, with amino acid specificity.  Oxidized insulin chain B peptide was 
hydrolyzed after only 4 h of treatment at pH 7.0 and 60 °C using ZrCl4 in the presence of 4,13-
diaza-18-crown-6. MALDI-TOF and ESI LC-MS mass spectra indicated that insulin chain B was 
hydrolyzed by ZrIV at the Gly8-Ser9, Ser9-His10, and Gly20-Glu21 amide bonds within the 
oligopeptide.  To our surprise, the cysteine sulfonic acid sequences Cys(SO3H)7-Gly8 and 
Cys(SO3H)19-Gly20 were also cleaved.  To the best of our knowledge, this constitutes the first 
example of metal-assisted hydrolysis of a Cys(SO3H)-Xaa amide bond.  This is significant in 
  
light of the fact that cysteine sulfonic acid formation in proteins is triggered by oxidative stress 
and has been associated with amyloid fibril formation, Parkinson’s disease, and other 
deleterious, physiological processes.  
Chapter III describes the metal-assisted hydrolysis of sphingomyelin which is a principle 
phospholipid component of animal cell membranes. The sphingomyelin assays showed evidence 
of metal-assisted hydrolysis after 20 h of treatment at lysosomal pH 4.8 and cytosolic pH 7.0 at 
both physiological temperature 37 °C and 60 °C. The metal ion CeIV was the most reactive, 
followed by ZrIV, and then HfIV. The goal of this work is to develop metal-based reagents to 
reverse the lethal build-up of sphingomyelin that occurs in lysosomes of patients suffering from 
Niemann-Pick disease. 
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CHAPTER I    INTRODUCTION:  METAL-ASSISTED HYDROLYSIS OF 
BIOLOGICAL MOLECULES. 
 
Hydrolysis of peptides, proteins, and lipids by metal complexes. 
 
Synthetic metallopeptidases as proteases.  
Proteases are a useful tool for protein and peptide research because of their capability to 
selectively cleave proteins or peptides for sequencing, separation of proteins of interest from 
fusion protein expression, proteomics, and peptide mapping. The categories of proteases 
currently used include enzymatic proteases such as trypsin, chymotrypsin, and Lys-C; chemical 
proteases including cyanogen bromide; and synthetic metalloproteases which are still in the 
development stage. Synthetic metalloproteases are rapidly emerging as a novel protease category 
because of the unique physical and chemical properties of each metal complex.1 Metal-ligand 
complexes can be designed to hydrolyze the peptide amide bond.  Ideally, those complexes will 
rapidly cleave in high yields under mild conditions of temperature and pH, although many 
synthetic metalloproteases have been demonstrated to be effective only under extreme 
conditions. The ability to hydrolyze at specific amino acid residues is a key experimental 
element in order to produce discrete hydrolytic products that have no oxidative and other post-
cleavage modifications. 
Synthetic metallophospholipidases as hydrolytic agents.  
Studies on the development of metal-assisted hydrolysis of phospholipids are scarce with 
primary emphasis on lanthanide-assisted hydrolysis of p-nitrophenol-activated synthetic 
phospholipids at the phosphate ester bond. The studies were motivated by metallonucleases 
which cleave the phosphodiester bonds of RNA and DNA.2-8  The metal-assisted hydrolysis of 
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phospholipids is a potential area of therapeutic drug development with the aim of reversing the 
symptoms of phospholipid accumulation in lysosomal storage diseases such as Niemann-Pick 
disease and Sandhoff disease where a DNA mutation has caused lowered or negligible levels of 
phospholipase activity.  
Background and significance of phospholipids. 
Studies of phospholipid vesicles have provided insight into the cellular membrane 
environment either as models for membrane fusion or as detergent-solubilized liposomes. The 
investigations into the size distributions, composition, solubilization, and penetration of small 
molecules or ions have provided evidence to support a variety of mechanisms and scenarios for 
diseased states.  
One example of membrane composition that involves sphingomyelin is the lipid raft 
which associates with certain proteins involved in cell signal pathways. Sphingomyelin-
cholesterol domains within cellular membranes form localized distributions or cholesterol-
enriched microdomains called lipid membrane rafts due to the different miscibilities of 
phospholipids and cholesterol which together serve as transporters of proteins, lipids, and other 
second messenger molecules.9 These rafts are more resistant to Triton X-100 solubilization at 4 
°C than 37 °C, and, for the lipids in the fluid state, solubilization at lower temperatures requires 
less detergent, whereas, for the lipids in the gel state, solubilization at lower temperatures 
requires more detergent. The rafts exist in a third state called the liquid-ordered phase.10 
            Under non-equilibrium conditions, the bilayers of vesicles in biomembranes have been 
shown by fluorescence probe systems such as carboxyfluorescein to either leak the inner 
contents or fuse into aggregates.11a-e Sphingomyelin:phosphatidyethanolamine:cholesterol (2:1:1 
molar ratio) vesicles were treated with sphingomyelinase enzyme with subsequent ceramide 
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production which resulted in vesicle leakage of the aqueous contents. When vesicles of the same 
composition were treated with bacterial phospholipase C to produce a diacylglycerol product, the 
opposite effect of vesicle fusion and aggregation occurred rather than leakage. The effects of the 
enzymatic production of ceramide or diacylglyerol gives insight into the bilayer destabilization 
and fusion caused by these products. Triton X-100 was used to create complete leakage and 
solubilization of the bilayers.11b 
The penetration of small molecules into vesicles has been simulated by studies where 
fluorescent molecules such as carboxyfluorescein, N-phenyl-1-naphthylamine (NPN), 1-anilino-
8-naphthalene sulphonate (ANS) are entrapped inside the liposomes and therefore emit little 
fluorescence. As the vesicle is solubilized due to a surfactant such as Triton X-100, the bilayer 
integrity changes with subsequent release of the vesicle contents of the carboxyfluorescein. As 
the contents leak out, the fluorescence increase is determined quantitatively. With ANS or NPN 
probes, the interaction of the fluorescent molecules with the lipids or detergents causes a shift in 
the λmax to shorter wavelengths, especially with probe-lipid bilayer interactions compared to 
probe-detergent micelles interactions.11a-e 
The size and shape of sphingomyelin vesicles have been studied with dynamic light 
scattering, turbidity measurements, and electron or atomic force microscopy.12a-b The size 
distribution of vesicles is determined because of the different biophysical characteristics that 
result from the vesicle size categories. The gel to liquid-crystalline phase transition temperature 
is determined by differential scanning calorimetry. Isothermal titration calorimetry has been the 
main instrumentation for the study of detergent partitioning into bilayers. Considerable attention 
has been given to the breakdown of lamellar structures to form lipid-surfactant mixed micelles 
through the use of detergents such as Triton X-100. Optical measurements of the turbidity 
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constitute a method to observe changes in vesicle size from aggregation with a turbidity increase 
or from solubilization followed by decreased turbidity. 
 Extensive work on the solubilization of vesicles by Triton X-100 has been done to 
determine the progressively complex structures that form with increasing detergent 
incorporation. 11a,b,c,e  Since sonicated vesicles with entrapped drug molecules can serve as drug 
carriers, the Triton X-100 detergent serves to model the changes that occur upon an encounter 
with physiological amphiphiles that can also solubilize vesicles. Five stages of progressive 
transformation have been described in the incorporation of Triton X-100 into vesicles to form 
micelles. 12b 
Background of the therapeutic use of metals. 
The use of inorganic complexes in medicinal chemistry for intended biological disease 
targets is an emerging field.13 The metal-ligand complexes which demonstrate no cytotoxicity 
can be delivered to specific tissues, cells, or receptors. Numerous metals under investigation as 
drugs include Al, Ga, In, Ti, Ru, Pt, Au, and Sn as anticancer drugs; Cu, Zn, Ag, Hg, and Bi as 
antimicrobial agents; Au as an antiarthritic agent, Li as an antidepressant, Fe and Zn as 
antihypertensive drugs; Li, Pt, Au, W, and Cu as antiviral drugs; Bi as an antiulcer drug, Al, Na, 
Mg, and Ca as antacids; and metalloporphyrins for use in photodynamic therapy. The ions of PtII, 
AuI, and BiIII are the most prevalent examples with the platinum(II) anticancer agents such as 
cisplatin and carboplatin; AuI in the form of antiarthritic drugs while BiIII subcitrate and 
subsalicylate serve as antiulcer drugs.  The Pt drugs are known to target DNA while AuI  binds 
DNA very weakly, but binds cysteine-34 of serum albumin very strongly via thiolate exchange 
reactions.  Under oxidative conditions of inflamed joints, AuI is oxidized to AuIII in the 
lysosomes as a result of antigen processing by proteases. Using the FeIII serum transport protein 
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transferrin with ruthenium and titanium incorporation, the metals are released inside cells 
especially in the acidic environments such as endosomes. BismuthIII interferes with the uptake 
and metabolism of FeIII used by bacterium such as Helicobacter pylori.14 By coupling metal 
properties with natural biodistribution and physiological pathways, a metal complex can be 
targeted to specific organelles.15  
Many studies16-30 have investigated the biological fate of ZrIV in the form of 
organometallic and inorganic complexes and in radioactive or non-radioactive forms in humans, 
animals, or cells using several techniques especially positron emission tomography. A few trends 
have been discerned, e.g., ZrIV complexed with albumin or antibodies is organ-specific and does 
not accumulate in the bone. Other researchers have noted that zirconium is initially retained in 
the soft tissue and then slowly accumulates in the bone. The metal is able to cross the blood-
brain barrier and the placenta. Inorganic zirconium complexes either accumulate in the bone or 
are cleared by the kidneys. Zirconium species in deodorants and anti-perspirants produced 
allergic responses with migration inhibitory factor and lymphocyte production and positive 
antigenicity. In contrast, Zr salts acted as lymphocyte mitogens and augmented the response of 
immune cells. Human peri-implant cells including fibroblasts, lymphocytes, osteoblasts-like 
MG-63 cells were grown with 0.001-10 mM ZrCl4. At concentrations < 0.1 mM ZrCl4, the metal 
did not reduce proliferation of the cells. Only concentrations > 1.0 mM ZrCl4 produced toxicity 
to the cells.16-30 
While CeIII hepatotoxicity injury has been extensively documented31a-c, a few studies 
have documented cerium(IV) toxicity mainly via reaction with sulfhydryl-containing compounds 
such as cysteine amino acids. CeriumIV was shown to generate thiyl free radicals in the cellular 
systems containing cysteine which caused serious damage in the cell function especially the 
6 
 
muscular protein myosin and the contractile protein actin from rabbit skeletal muscle with 
conformational changes that affected activity such as the ATPase activity of myosin.31d  
Cerium(IV) sulfate was shown to bind lactoferrin which is a metal-binding protein in the 
transferrin family.  The two Ce4+ ions occupied the same position in Ce2Lactoferrin as the typical 
in vivo Fe2Lactoferrin.31e 
An important development in metal-based drug design are metallocene complexes with 
transition metals which have demonstrated antitumor effects with antiproliferative properties.32-35 
Metallocenes are neutral complexes of distorted tetrahedral coordination geometry of two h5-
cyclopentadienyl rings between transition metal such as Ti, V, and Zr. Titanocene has been used 
unsuccessfully in Phase 2 clinical trials.  The dichlorides are the most common metallocenes and 
represented by formula (Cp)2MCl2 where M is metal and Cp is the cyclopentadienyl group.  The 
metallocenes are ionic and cationic salts without halides.  The anion is usually trichloroacetate, 
picrate, or tetrahalideferrate (III). The largest use of organozirconium compounds is as 
polymerization catalysts for ethylene polymerization and for transition-metal-catalyzed cross-
couplings.  A related zirconocene compound is Schwartz Reagent (Cp2ZrHCl) which has been 
used for hydrozirconation in the production of antiestrogen drugs.32-35 
 Zirconium is nontoxic, unlike some other transition metals, so its use as a metallocene 
therapeutic agent merits further exploration. The lack of cytotoxicity of the zirconocene was 
noted in a study where zirconocene was combined with adriamycin for therapeutic 
investigations, although, the ZrIV-adriamycin complex was devoid of antitumor activity.36 The 
titanium metallocenes have shown strong antiproliferative activity against fluid Ehrlich ascites 
tumor, solid B16 melanoma, colon 38 adenocircoma, and Lewis lung carcinoma cell lines. The 
metallocenes (Cp2MX2) are generally believed to effect inhibition of nucleic acid metabolism, 
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mitotic activity, as well as accumulate in the nuclear heterochromatin of the tumor cells.35,37a-b  
In nude mice studies, metallocenes showed antiproliferative effects against implanted human 
 tumors. Comparisons of titanocene dichloride and dibromides to 5-fluorouracil showed similar 
efficacies.  Substitution of the cyclopentadienyl groups reduces tumor inhibition substantially.32 
Mechanistic studies of peptides. 
 Transition metal ions and complexes have been investigated for their catalytic ability to 
hydrolyze the polypeptide backbone under various conditions of temperature and pH.  Unlike 
oxidative cleavage in which the peptide backbone α-carbon hydrogen atoms are abstracted by 
metal-generated hydroxyl radicals to produce multiple, fragmented peptide products, the 
hydrolysis of peptides involves addition of water across the amide bond in the backbone 
followed by release of two hydrolyzed, native peptides with free N-terminal and C-terminal 
groups as shown in Figure 1.1. The metal-assisted hydrolysis of the peptide would yield products 
which are comparable to natural metal-activated peptidase reactions. 
The proposed role of proteolytic metals ions in promoting hydrolytic reactions in peptides 
may include molecular scaffolding for proper juxtaposition of a hydroxide nucleophile to the 
substrate, direct activation of the carbonyl bond by a free metal ion, charge neutralization and 
stabilization of the negatively-charged tetrahedral intermediate formed by coordination of the 
metal’s electropositive charge to a negatively charged carbonyl oxygen, and/or serve as a metal-
hydroxide nucleophile at neutral pH where many metals exist as a hydroxide complex due to the 
deprotonation of the waters of hydration.  Four proposed schemes for mechanisms of the peptide 
hydrolysis are shown in Figure 1.2. A tetrahedral intermediate is formed in all cases.1,3 Scheme I 
shows the direct coordination of the metal to the carbonyl oxygen while a hydroxide nucleophile 
from the aqueous solution adds to the carbonyl carbon. In Scheme II, a metal-coordinated 
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hydroxide species which is generated by deprotonation of a metal-bound water of hydration, 
adds a hydroxide group to the carbonyl. Scheme III involves a multiple coordination of a 
hydroxide nucleophile and the amide bond’s carbonyl oxygen while the attached hydroxide 
nucleophile adds to the carbonyl carbon. The ZrIV metal used in the studies described in this 
dissertation is oxophilic and forms complexes with a high coordination numbers such as the 
coordination of both the amide carbonyl oxygen and the hydroxide group that Scheme III entails. 
Scheme IV is a variation of Scheme III where the metal-hydroxide species activates the carbonyl 
oxygen, and the coordinated hydroxide acts as a base toward another acidic water molecule in 
solution whose deprotonated hydroxide nucleophilic species then attacks the amide carbonyl 
carbon. The proposed tetrahedral intermediate in schemes I, II, and III forms a metal-coordinated 
intermediate whose RNH-  M+ leaving group may not be labile and may form a hydrolytically 
inactive species. However, Scheme IV involves protonation of the RNH- group by the metal-
bound water of hydration in an acid-base reaction to form a more labile RNH2 leaving group. 
Aqueous speciation of certain metals.  
When strong Lewis acid metals are bound by waters of hydration in aqueous solutions, 
the metals often lower the pKa of the attached waters from 15.7 to lower, acidic pKa values. For 
example, the pKa of metal-bound water molecules are ≤ 1 for ZrIV, HfIV, and CeIV so that the 
concentration of metal-hydroxide nucleophiles from the deprotonated water bound metal are 
abundant at neutral and mildly acidic pH values. The precise aqueous speciations of ZrIV, HfIV, 
and CeIV are not known, although ZrIVaq equilibrates at low pH as [Zr4(OH)8(H20)16Cl6]2+  
(tetranuclear ion) and [Zr8(OH)20(H2O)24Cl12] + 4H+ + 4H2O (octanuclear ion). At higher pH 
values, these ZrIV aqueous complexes speciate to form insoluble gels and precipitates.37  
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Figure 1.1.  The hydrolysis of the peptide bond to yield two intact peptides.1 
 
 
Figure 1.2.  Four proposed mechanisms leading to a tetrahedral intermediate in metal-assisted 
peptide hydrolysis.1 
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Figure 1.3.  The PdII-assisted coordination with a histidine residue in an X-Y-His peptide 
sequence. In weakly acidic solutions, the PdII reagent cleaves the second peptide bond upstream 
from the anchoring histidine residues.40h 
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The aqueous speciation of CeIV above pH 4 results in the formation of insoluble CeIV-hydroxide 
gels. The dimeric CeIV-hydroxo species [CeIV2(OH)4]4+ is attributed to be the reactive entity in 
several studies.4b,39a- 
Background and significance of metal-assisted hydrolysis of peptides. 
Transition metals.  
  Metal ions and complexes of CeIV, CoII, CeII, CuII, MoIV, NiII, PdII, PtII, ZnII, and ZrIV 
have been used to hydrolyze peptide bonds.1,39-43 For CuII, CoIII, NiII, PdII, and PtII, large proteins 
and peptides have been cleaved.  An example is the PdII hydrolysis of methionine enkephalin at a 
–G|X-H bond after 1-2 days at 60 °C, and pH 0.5.40e  Figure 1.3 illustrates the PdII-assisted 
coordination with a histidine residue in an X-Y-His peptide sequence. In weakly acidic solutions, 
the PdII reagent cleaves the second peptide bond upstream from the anchoring histidine 
residues.40h Another example is the CuII hydrolysis of insulin chain B at a –G|S-H bond after 4 h 
at 25 °C, and pH 2.5.40f   NiII hydrolyzed a histone peptide at the –E|S-H bond after 134 h at 37 
°C, and pH 7.4.40g  While some metals demonstrate unique specificities and good hydrolytic 
yields, only a few of the reaction conditions cited in the literature are at non-denaturing pH and 
temperature. The synthetic metalloprotease preference is for hydrolytic metal complexes with 
unique specificities toward certain amino acids, that can not only developed as catalytic agents 
that cleave under physiological conditions, but also as proteolytic tools for protein structural 
elucidation by mild proteolysis where the tertiary and quaternary protein structures are not 
disturbed.  The ZrCl4 salt in the presence of 4,13-diaza-18-crown-6 was used by our research 
group to hydrolyze an extensive series of dipeptides to determine the ZrIV specificity toward 
amino acid residues.  ZrIV showed a distinct preference for hydrolysis of dipeptides with 
negatively charged and oxygen-containing sidechains as determined by LC colorimetric 
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techniques.43   Using this information, we then wanted to adapt this same ZrIV/ 4,13-diaza-18-
crown-6 complex to hydrolyze larger peptides and proteins and to study the products using mass 
spectral techniques of matrix-assisted laser desorption ionization (MALDI) and high 
performance liquid chromatography electrospray mass spectrometry (HPLC-ESI-MS), which 
allow not only unequivocal determination of molecular weight, but also subsequent confirmation 
of hydrolysis products by tandem mass spectrometry (MS/MS) analysis. 
Zirconium(IV).   
As mentioned previously, transition metal complexes that efficiently hydrolyze peptides 
under non-denaturing conditions of pH and temperature represent an emerging area of research.  
Zirconium(IV), a transition metal ion with a [Kr] ground state configuration,  has been the major 
emphasis of our metallopeptidase investigations because of its strong Lewis acid strength, fast 
ligand exchange kinetics, redox inactive state, and its oxophilic characteristics as summarized in 
Table 1.1. Zirconium(IV) in the presence of 4,13-diaza-18-crown-6 has outstanding proteolytic 
ability at pH 7.0 and 60 °C with a selectivity toward peptide amide bonds in dipeptides with 
negatively-charged, oxygen amino acid side chains.1,43  Consequently, ligands with similar 
structures to or substructures of the 4,13-diaza-18-crown-6 have been investigated by our 
laboratory as possible ZrIV complexes. Because of mild experimental conditions of pH and 
temperature employed, several of the ZrIV complexes showed promise for future use in the study 
of protein solution structure, the generation of semi-synthetic proteins, the proteolytic cleavage 
of bioengineered fusion proteins, and therapeutics.  
Our first aim in the ZrIV-assisted hydrolysis of peptides was to apply the same ZrIV-4,13-
diaza-18-crown-6 complex used in our preliminary dipeptide studies43 to larger peptides and 
proteins and to use different detection techniques to study reaction products especially mass  
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Table 1.1.  Properties of zirconium(IV). 
 
 
Zirconium(IV) Properties 
Lowers the pKa of bound water from 15.7 to ≤ 0.6 
Redox inactive (do electron configuration) 
Stable +4 oxidation state 
Complexes have high coordination number 
Oxophilic 
Hydrolyzes phosphodiester bonds 
Strong Lewis acids 
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spectrometry ionization techniques.  An initial study of metal-assisted hydrolysis of oxidized 
insulin chain B, from the biologically active insulin peptide hormone that regulates the cellular 
uptake, utilization, and storage of glucose, amino acids, and fatty acids, was undertaken. 
As described in Chapter II, our data demonstrates that ZrIV is capable of hydrolyzing insulin 
chain B in a sequence specific fashion after only 4 h of treatment at 60 °C and pH 7. 
Background and significance of metal-assisted hydrolysis of phospholipids. 
 Under normal conditions, most phospholipids are metabolized in the acidic lysosomes of 
cells that contain lipases and other hydrolytic enzymes.45-46  Many inherited phospholipid-related 
disorders are the result of the accumulation of specific unmetabolized phospholipids with 
manifestation of clinical symptoms due to decreased activity of a defective hydrolytic enzyme. 
The disorders associated with defective lysosomal enzymes are categorized as lysosomal storage 
diseases or LSDs and include more than forty diseases resulting from  chromosomal mutations. 
Examples include Niemann-Pick disease types A and B where defective acid sphingomyelinase 
causes sphingomyelin and associated cholesterol accumulation in lysosomes.  In Gaucher’s 
disease, glucocerobroside accumulates from the lack of metabolism due to a defective 
glucocerobrosidase enzyme. Fabry’s disease results from a deficiency of the enzyme alpha 
galactosidase A which normally metabolizes a glycosphingolipid known as 
globotriaosylceramide or Gb3.47 
Mechanistic studies of metal-assisted phosphate ester bond hydrolysis. 
Mechanistic studies on phosphate ester hydrolysis of phospholipids are scarce. The Lewis 
acids of ZrIV, HfIV, and CeIV are classified as hard acids and oxophilic so that the metals are 
capable of activating a phosphate ester bond towards nucleophilic attack by charge neutralization 
and the provision of metal-bound hydroxides due to their ability to lower the pKa of the bound 
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waters of hydration.48-49  Metal-assisted catalysis of the activated phosphate ester bond in bis(p-
nitrophenyl)-phosphate or BNPP which is a model for DNA phosphodiester linkage has been 
studied to compare the rates of hydrolysis by various metals of which the lanthanide metals, 
especially the highly reactive CeIV, have the highest rates.6  The CeIV ion, as cerium(IV) 
ammonium nitrate was fifty times more reactive than other lanthanides such as EuIII, LaIII, or PrIII 
in a Brij-induced micellar preparation of BNPP.6  Other applications of metal-assisted catalysis 
have been applied as nucleases toward phosphate ester hydrolysis with RNA more susceptible to 
hydrolysis than DNA. ZrIV was shown to hydrolyze bis(p-nitrophenyl)phosphate in a pH 
dependent fashion as well as CeIV with maximum reactivity at pH 4.  In the same study, ZrIV (5 
mM) salt hydrolyzed the phosphodiester linkage in the DNA dinucleotide thymidylyl (3′→5′) 
thymidine in the presence of 10 mM Tris at pH 5.5 and 20 °C at a rate with a half-life of 28 
days.2  
Summary of mechanisms. 
  The general agreement about the mechanism of metal-assisted cleavage of the phosphate 
ester bonds in lipids is that the positively-charged metal binds and partially neutralizes the 
negatively-charged P-O-  oxygen while activating and polarizing the substrate for nucleophilic 
attack by the metal’s attached hydroxyl nucleophile (M-OH) which attacks the phosphate group 
of the P=O functional group. Figure 1.4 shows an example of this mechanism with the 
Cu([9]aneN3)Cl2-assisted hydrolysis of an activated phosphate ester. The transition state and 
intermediates show the intramolecular nucleophilic attack by the metal-bound hydroxide.50 
Lanthanide ions LaIII, EuIII, and LuIII were used in modeling RNA cleavage and catalysis 
via phosphate diester transesterification by studying the amount of released 4-nitrophenol from 
4-nitrophenolphosphate esters of propylene glycol following lanthanide- assisted hydrolysis. The 
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pH-rate profiles showed that the lanthanide hydroxide species [Ln(OH)2+] is the active catalyst 
and serves as a general base where two coordination sites are required for binding of both a 
hydroxide and a phosphate ester. The pseudo-first-order rate constants showed a pH dependence 
of increasing kobs with increasing pH and a maximum rate in the pH range 8.5-9.51 
Figure 1.5 shows a proposed schematic of the ZrIV hydrolysis of the sphingomyelin 
phospholipid with a Zr-OH bound transition state to release choline and a phosphoceramide. The 
release of choline is one of two possible pathways of ZrIV hydrolysis. The release of 
phosphocholine is the physiological pathway. 
Significance of metal-assisted hydrolysis of sphingomyelin. 
Niemann-Pick disease is an incurable, autosomal recessive, lysosomal storage disorder 
with two phenotypes A and B.52 Type A primarily affects Ashkenazic Jews with infant mortality 
while type B affects other diverse ethnic groups with middle age mortality. The defective 
enzyme acid sphingomyelinase has only 1-3% normal activity in type A while type B has 10 - 
60% of normal enzyme activity resulting in fatal accumulation of sphingomyelin in the 
lysosomes. The affected organs in type A are the spleen, lymph nodes’ monocyte-macrophage 
system, liver, kidneys, brain, and lung, while type B has similar patterns except for no 
accumulation in the brain.  Cholesterol also builds up in the lysosomes, most probably due to the 
interdispersion of cholesterol with sphingomyelin in the periplasmic membrane. Enzyme 
replacement and chemical chaperones have had limited therapeutic success in Niemann-Pick 
patients. A novel therapeutic cure based on ZrIV-assisted phospholipid hydrolysis is a developing 
concept in our laboratory to decrease this fatal accumulation of the sphingomyelin. Since ZrIV is 
redox-inactive and possesses low cellular toxicity, a ZrIV complex which efficiently 
hydrolyzessphingomyelin at the same hydrolytic bonds as the acid sphingomyelinase enzyme  
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Figure 1.4.  Proposed mechanism of the Cu([9]aneN3)Cl2-assisted hydrolysis of an activated 
phosphate ester showing the transition state and intermediates.50 
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Figure 1.5.  Proposed schematic of the ZrIV hydrolysis of sphingomyelin with a Zr-OH bound 
transition state to release choline and a phosphoceramide. 
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may function as an enzymatic mimic. It is worthwhile to investigate the pH-dependent 
reactivities of metals to determine the increase in metal-assisted hydrolytic cleavage in the 
lysosomes compared to cytosol. Several rat studies have shown that zirconium(IV) is localized in 
the lysosomes upon ingestion which suggests a possible therapeutic ability to target the diseased 
organelle. Electron probe x-ray microanalysis of thin tissue sections from rat have shown that 
ingested ZrIV plus HfIV and CeIV accumulates in the lysosomes as a phosphorus complex 
probably due to the activity of acid phosphatase.54a  Zirconium(IV), injected as zirconium 
sulfate, localized in the lysosomes of the lymph node macrophages as a phosphorus complex.54b 
The optimal hydrolysis of DNA and acetylated peptides by ZrIV has been shown to be higher at 
(lysosomal) pH 4.8 than (cytosol) pH 7.0.2,53 A proposed mechanism for the ZrIV-assisted 
hydrolysis of sphingomyelin to release choline and a phosphoceramide is shown in Figure 1.5. 
Hydrolysis could likely occur on the other side of the phosphate ester bond to release 
phosphocholine and ceramide which is similar to the in vivo enzymatic reaction. The presence of 
the Triton X-100 compound, used in our studies for solubilization purposes, has been applied 
therapeutically to the encapsulation of biodegradable nanoparticles with drugs since the 
surfactact stabilizes the polymer particles during the microencapsulation process.55a-b 
Research objectives. 
In Chapter II of this dissertation, our research goals were to design and evaluate ZrIV 
complexes which hydrolyze the amide bond of peptides and proteins with amino acid residue 
specificity. We have demonstrated the proteomic capabilities of the ZrIV-assisted hydrolysis of 
larger biological proteins by mass spectral data and determined post-reaction side modifications 
to the protein or its products. We found that the ZrIV in the presence of 4,13 diaza-18-crown-6 
hydrolyzes not only a Gly-Glu amide bond, but also the oxidized cysteine sulfonic acid residues 
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in the insulin chain B protein. Clinically, these oxophilic ZrIV complexes can perhaps be 
developed to target specific disease-related proteins that have irreversible oxidation especially 
cysteine oxidation in order to prevent cellular accumulation. 
In Chapter III of this dissertation, our aim was to expand the studies of ZrIV complexes 
with comparison to other metals to observe the hydrolysis of an unexplored class of molecules of 
phospholipids, namely sphingomyelin. To the best of our knowledge, we are the first to present 
the metal-assisted hydrolysis of sphingomyelin.  The impact of this research is the development 
of therapeutic applications to Niemann-Pick diseases type A and B which exhibits fatal 
symptoms due to the accumulation of sphingomyelin in the lysosomes. We found that the 
tetravalent metals ZrIV, CeIV, and HfIV efficiently hydrolyzed sphingomyelin in good yields as 
quantified by an Amplex Red and inorganic phosphate assays. The effects of Triton X-100 and 
cholesterol on the hydrolysis of sphingomyelin were investigated. 
The conclusions of the contributions of the metal-assisted hydrolysis of two classes of 
biological molecules including proteins and phospholipids are presented in Chapter IV. The 
specific hydrolytic capabilities of certain metals to mimic enzymatic reactions that are defective 
in diseased states represents progress in an emerging research area. 
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CHAPTER II    HYDROLYSIS OF INSULIN CHAIN B USING ZIRCONIUM(IV) AT 
NEUTRAL PH. 
 
 (This chapter is taken verbatim from an article by Sarah S. Cepeda and Kathryn B. Grant,  New 
Journal of Chemistry, 2008, 32, 388-391. Sarah S. Cepeda conducted the experiments and 
contributed to the writing of the article.  The final version of the manuscript was written by Prof. 
Kathryn B. Grant. Following the chapter is an unpublished epilogue showing additional data) 
 
Abstract. 
 
Zirconium(IV) hydrolyzes the 30-mer oligopeptide oxidized bovine insulin chain B after 
4 h to 8 h of treatment at pH 7.0 and 60 °C: MALDI-TOF and HPLC-ESI-MS and MS/MS data 
show significant levels of cleavage at Gly8-Ser9, Gly20-Glu21, Ser9-His10, Cys(SO3H)7-Gly8, 
and Cys(SO3H)19-Gly20 amide bonds within the oligopeptide. 
Introduction. 
There has been widespread interest in the development of metal complexes that 
hydrolyze peptide amide bonds under mild conditions of pH and temperature.1  These 
compounds are of great importance due to their potential applications in the analysis of protein 
solution structure, in protein engineering, and in therapeutics.1d,f,h,2  Our own research efforts 
have primarily focused on zirconium (IV). Because of its enhanced Lewis acid strength, 
oxophilicity,3 tendency to form complexes with high coordination numbers,3 and rapid ligand-
exchange kinetics,4 this metal center should be able to catalyze peptide hydrolysis by activating 
an amide carbonyl carbon in the peptide backbone while delivering a hydroxide nucleophile to 
the scissile amide bond.1f  Recent efforts in our laboratory have demonstrated that ZrIV in the 
presence 4,13-diaza-18-crown-6 has excellent reactivity: t1/2 values are 5.3 ≤ 0.1 h and 36.6 ≤ 2.7 
h for ZrIV-assisted hydrolysis of the dipeptide Gly-Glu at pH 7.1/60°C and at pH 7.3/37°C.1f 
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(These half-lives represent significant rate enhancements compared to the t1/2 of ~250 years for 
spontaneous hydrolysis of unactivated peptide amide bonds at pH 7.0 and 37°C).5 The formation 
of insoluble ZrIV precipitates during the cleavage reactions led us to speculated that hydrolysis of 
peptides by ZrIV/4,13-diaza-18-crown-6 might have a heterogeneous component similar to 
peptide hydrolysis by lanthanide hydroxide gels.6 Yet, in spite of the attributes of ZrIV, the 
largest peptide to have been hydrolyzed by this metal center was Ala-Gly-Asp-Val.1f To address 
this size limitation, herein we report efficient, ZrIV-assisted hydrolysis of the 30-mer 
oligopeptides oxidized bovine insulin chain B. 
Results and discussion. 
  In a typical cleavage reaction, 500 uM to 1 mM of oxidized bovine insulin chain B was 
added to 20 mM of 4,13-diaza-18-crown-67 in the presence or absence of 10 mM of ZrCl4.  
Hydrolysis reactions were allowed to proceed at pH 6.9-7.2 and 60°C.  Aliquots were removed at 
~t = 0 h, 4 h, and 8 h time points, quenched with the strong chelating agent EDTA, and then 
analyzed by HPLC-electrospray ionization mass spectrometry (ESI-MS) or by matrix-assisted 
laser desorption ionization time-of-flight (MALDI-TOF) MS.  Mass spectral peak assignments of 
peptide hydrolysis products were made using FindPept software and ESI tandem mass 
spectrometry (MS/MS) (Figure 2.1(a) and (b)). Each of the peptide fragments produced by 
ZrIV/4,13-diaza-18-crown-6 was defined as either an apparent major, intermediate, or trace 
product depending on its percent relative abundance in the HPLC-ESI chromatograms and 
MALDI-TOF mass spectra.  In Figure 2.1(c) is the primary amino acid sequence of insulin chain 
B showing the positions of peptide amide bond hydrolysis indicated by the MS data.  In addition 
to percent relative abundance, Tables 2.1 and 2.2 summarize observed vs. calculated m/z values. 
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 The HPLC-ESI chromatograms and MALDI-TOF mass spectra in Figure 2.2 and Figure 
2.3 reveal the time-dependent appearance of prominent insulin chain B peptide hydrolysis 
products B, C, D, E, F, G, I, K, K‡, L, W, and X. It is evident that shorter peptide fragments B, 
D, F, I, K, K‡, L, W, and X become more dominant as the reaction proceeds from t = 4 h to t = 8 
h, while the larger fragments C, E, G are prominent only at t = 4 h (Figure 2.2).  
The cleavage yields corresponding to the HPLC-ESI chromatograms shown in Figure 2.2 
were estimated by taking the sum of the peak areas of all the peptide hydrolysis products, 
dividing this sum by the total peak areas of the peptide hydrolysis products added to the peak 
area of any remaining unhydrolyzed peptide, and then multiplying the quotient by 100: 
hydrolysis yield = [sum of all peptide hydrolysis product peak areas / (sum of all peptide 
hydrolysis product peak areas + unhydrolyzed insulin chain B peak area)]  x 100.  In the 
presence of ZrIV/4,13-diaza-18-crown-6, these values were 0% at t = 0 h, 15 % at t=4 h and 51 % 
at t = 8 h (pH 7.0 and 60 °C).  In parallel control reactions in which ZrCl4 was substituted by 
equivalent volumes of water, corresponding values were minimal (0 % at t=0 h, 0 % at t=4 h and 
3 % at t= 8 h). 
 As expected, a larger number of peptide fragments was detected by HPLC-ESI-MS in 
comparison to MALDI-TOF MS. (In complex mixtures of analytes, competition for charge can 
lead to ion suppression.  As a result, pre-separation is often needed to enhance sensitivity).8  
Notwithstanding, the MALDI and HPLC-ESI experiments are in good general agreement (Figure 
2.1, 2.2, 2.3).  The data collectively indicate that ZrIV/4,13-diaza-18-crown-6 produces major 
amounts of hydrolysis at the following five amide bonds: Gly8-Ser9, Gly20-Glu21, Ser9-His10, 
Cys(SO3H)7-Gly8, and Cys(SO3H)19-Gly20. With respect to Gly8-Ser9, cleavage of Xaa-
Ser(Thr) in peptides and proteins containing the sequence Xaa-Ser(Thr)-His has been extensively 
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documented for CuII,2b,9a,b,e,f NiII,1b and PdII, 9b-d and is thought to involve an N→O acyl 
rearrangement promoted by the hydroxyl group side chains of serine or threonine.1b,9a,d   We also 
expected to observe significant levels of hydrolysis at Gly20-Glu21 and at Ser9-His10.   In a 
previously published report, we demonstrated that ZrIV/4,13-diaza-18-crown-6 displays a clear 
preference for hydrolysis of neutral and negatively charged peptides containing glycine or amino 
acids with oxygen-rich side chains.1f (In fact, Gly-Glu was the most reactive of the 16 dipeptides 
studied.)  The oxophilicity of ZrIV combined with electrostatic interactions between this 
positively charged metal center and negatively charged Cys(SO3-) could account for the efficient 
hydrolysis of the Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20 amide bonds in bovine insulin 
chain B.  In addition to the five major products, ZrIV/4,13-diaza-18-crown-6 produced apparent 
intermediate amounts of hydrolysis at: Leu6-Cys(SO3H)7, Arg22-Gly23, and Gly23-Phe24.  
This pattern again may reflect the preference of ZrIV for hydrolysis of peptides with glycine or 
oxygen-rich side chains.  As shown in Figure 2.1 and Tables 2.1 (in ESI), trace amounts of 
hydrolysis were seen at five sites within the oligopeptides. 
Up until now, hydrolysis of oxidized insulin chain B has been studied using salts and/or 
complexes of CuII,9b,g PdII,9b,c PtII,9g and ZnII 9h. These experiments were conducted under acidic 
conditions (pH 2.0 to 2.5) at temperatures ranging from 40 °C to 60 °C.  Hydrolysis reactions 
were studied by ESI-MS,9b,g,h HPLC-ESI-MS,9g MS/MS,9g,h and MALDI-TOF MS.9c  The data 
showed that metal binding sites included the N-terminal amino group of Phe1 (CuII, PdII, and 
PtII),9b,c,g the imidazole side chains of His5 and His10 (CuII, PdII, PtII, and ZnII), 9b,c,g,h and Arg22 
(ZnII).9h  If the metal-peptide complexes formed were hydrolytically active, then amide bond 
hydrolysis occurred in close proximity to the anchoring amino acid residue.  Thus, the following 
insulin chain B peptide amide bonds were hydrolyzed: Phe1-Val2 (CuII),9g Asn3-Gln4 (CuII, PdII,  
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Figure 2.1.  Peptides detected in (a) HPLC-ESI and (b) MALDI-TOF mass spectra.  The colors 
blue, red, and green identify apparent major, intermediate, and trace hydrolysis products, 
respectively. “†” = deamidation of Asn3 to Asp3, and/or Gln4 to Glu4. “‡” = lactamization of 
Glu21 to pyroglutamate21 (pyroGlu21). (c) Corresponding ZrIV/4,13-diaza-18-crown-6 cleavage 
sites superimposed on the amino acid sequence of oxidized bovine insulin chain B. 
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Figure 2.2.  HPLC chromatograms of 500 µM of insulin chain B treated with 10 mM ZrCl4 in 20 
mM 4,13-diaza-18-crown-6 for t = (a) 0  h, (b) 4 h, and (c) 8 h (pH 7.0 and 60 °C). Peak A is 
unhydrolyzed insulin chain B. Peaks B, D, F, I, K, and peaks L, X, W, K‡, C, E, G correspond to 
apparent major and intermediate peptide hydrolysis products, respectively.  Trace hydrolysis 
products are in Table 2.1 (in ESI). Representative ESI mass spectra are in Figure 2.4 to 2.6 
“Crown” identifies the azacrown ether. “*” identifies Na-adducted monomer and Na-adducted 
cluster dimers of peak A. 
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Figure 2.3.  Representative MALDI-TOF mass spectra for hydrolysis of 1 mM of insulin chain B 
at (a) t = 0 h and (b) t = 4.2 h.  Reactions were run in 10 mM ZrCl4 and 20 mM 4,13-diaza-18-
crown-6 at pH 7.2 and 60 °C.  Peak A is unhydrolyzed insulin chain B.  Peaks K‡ and E and 
peaks I, G, and C correspond to apparent major and intermediate peptide hydrolysis products, 
respectively.  Trace hydrolysis products are listed in Table 2.2 (in MALDI).  Human angiotensin 
I is the internal standard.  All masses are singly charged unless otherwise indicated. 
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ZnII),9c,g,h His5-Leu6 (ZnII),9h Gly8-Ser9 (CuII, PdII, ZnII),9c,g,h His10-Leu11 (PtII),9g  and Glu21-
Arg22 (ZnII).9h In urea-denatured oxidized hog insulin chain B, PdII produced cleavage at Leu6-
Cys(SO3H)7 and at Gly8-Ser9.9b,10  Because no other cleavage sites were observed in any of the 
MS studies,9b,c,g,h the hydrolysis of Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20 amide bonds by 
ZrIV-4,13-diaza-18-crown-6 points to unprecedented cleavage of insulin chain B at 
approximately neutral pH. 
Metal salts of CeIII, CeIV, LaIII, ThIV, and ZrIV accelerate the lactamization of glutamate 
(Glu) to pyroglutamate (pyroGlu) at 70 °C over a weakly acidic to weakly alkaline pH range.11  
As shown in Figure 2.2 and Figure 2.3, ZrIV-assisted hydrolysis of oxidized bovine insulin chain 
B produces peptide fragment K (Glu21 to Ala30, m/z 1216) and a second prominent peptide K‡ 
(pyroGlu21 to Ala30, m/z 1198).  We attributed the appearance of the latter fragment to loss of 
water through lactamization of the N-terminal glutamate residue in peptide K.  Pyroglutamate 
formation was confirmed by ESI-MS/MS of K‡ which produced a pyroGlu immonium ion at m/z 
84.2.  In addition to lactamization of glutamate, CeIII, CeIV, LaIII, ThIV, and ZrIV ions accelerate 
the hydrolytic deamidation of glutamine and asparagines residues.12  In our experiments, HPLC-
ESI analyses of the ZrIV reactions detected the production of apparent trace quantities of the 
following three sets of insulin chain B peptides: B†(1) and B†(2); D†(1) and D†(2); and F†(1) 
and F†(2) (Table 2.1. in ESI). We then employed ESI-MS/MS sequencing to show that these 
fragments were produced by deamidation of parent peptides B, D, and F; in B†(1), D†(1), and 
F†(1), Gln4 in the corresponding parent was converted to Glu4; in B†(2), D†(2), and F†(2), 
Asn3 and Gln4 were deamidated to Asp3 and Glu4 (Figure 2.7).  Interestingly, deamidation of 
glutaminyl and asparaginyl residues occurs in vivo.  Because a correlation exits between protein 
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lifetime and total amide content, it has been suggested that deamidation may play a physiological 
role in triggering protein degradation.13 
 Up until now, the largest peptide to have been hydrolyzed by zirconium(IV) consisted of 
only four amino acid residues.1f  We have successfully addressed this apparent limitation in the 
present study. By using HPLC-ESI-MS and MS/MS, and MALDI-TOF MS, we have 
demonstrated that ZrIV/4,13-diaza-18-crown-6 facilitates hydrolysis of the 30-mer oligopeptides 
oxidized bovine insulin chain B at pH 7.0 and 60 °C.  Apparent major levels of cleavage were 
produced at Gly8-Ser9, Gly20-Glu21, Ser9-His10, Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20 
sequences, while intermediate amounts of hydrolysis were at Leu6-Cys(SO3H)7, Arg22-Gly23, 
and Gly23-Phe24, ZrIV/4,13-diaza-18-crown-6 was also shown to promote lactamization of N-
terminal Glu21 and deamidation of Asn3 and Gln4. To the best of our knowledge, this paper 
presents the first example of metal-assisted hydrolysis of a Cys(SO3H)-Xaa peptide amide bond.  
This is significant in light of the fact that the formation of cysteine sulfonic acid in proteins is 
triggered by oxidative stress and has been associated with amyloid fibril formation, Parkinson’s 
disease, and physiological processes involving oxidative stress response proteins.14  Our current 
work is focused on mechanistic studies that should enable us to design new zirconium ligands 
that optimize sequence specificity and increase the hydrolytic efficiency of ZrIV. 
 We thank the National Science Foundation for financial support under grant CHE-
0718634. 
Experimental. 
Peptide hydrolysis reactions.  A total of 500 µM to 1 mM of oxidized bovine insulin 
chain B (freshly dissolved in doubly distilled H2O) was added to 20 mM of 4,13-diaza-18-
crown-6 in the presence or absence of 10 mM of ZrCl4 (400 µL total volume).  The pH value of 
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the zirconium solution was adjusted at 25 °C to 6.9-7.2 by addition of the azacrown ether.7 
(Alternatively, in the absence of ZrCl4, pH was adjusted with HCl.)  Hydrolysis reactions wre 
then allowed to proceed at 60 °C and aliquots were removed at ~ t = 0 h, 4 h, and 8 h time points.  
Pre- and post-reaction pH measurements varied by only ≤ 0.12 units.  The aliquots were 
quenched at 4 °C with 1/10 volume of 0.5 M EDTA pH 8, and then analyzed by HPLC-ESI-MS 
or by MALDI-TOF MS.  Each of the peptide fragments produced by ZrIV/4,13-diaza-18-crown-6 
was arbitrarily defined as either an apparent major, intermediate, or trace product depending on 
its percent relative abundance in the HPLC-ESI chromatograms recorded at t = 4 h or t = 8 h 
(Table 2.1 in ESI) and in MALDI-TOF mass spectra recorded at t = 4.2 h (Table 2.2): 44 % to 
100 % for apparent major hydrolysis products, 12 % to 30 % for apparent intermediate 
hydrolysis products, 1 % to 5 % for apparent trace hydrolysis products. 
Mass spectrometry. 
HPLC-ESI-MS and HPLC-ESI-MS/MS. HPLC-ESI chromatograms and 
corresponding mass spectra were acquired over a scanning mass range of m/z  100 to 3000 on a 
Micromass Q-Tof Micro mass spectrometer equipped with a Waters 2695 HPLC.  Hydrolysis 
reactions were diluted 10-fold with doubly distilled H2O.  A 20 µL amount of each diluted 
solution was injected into a Waters Atlantis dC18 3 um, 100Å, 2.1 mm x 150 mm reversed-
phase HPLC column.  Separations were conducted over 109 min at 20 °C with a flow rate of 0.2 
mL min-1 and a mobile phase gradient elution scheme consisting of 2 % to 98 % of acetonitrile in 
0.1 % formic acid.  The ESI instrument settings were: electrospray needle voltage, + 3.0 kV; N2 
cone gas flow, 60 L h-1; N2 desolvation gas flow, 450 L h-1; capillary desolvation temperature, 
200 °C.   Spectra were acquired in positive ion mode (Figure 2.4, 2.5, 2.6, 2.7,) or in negative ion 
mode (Figure 2.8) with a scan time of 1.0 s. 
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HPLC-ESI-MS/MS sequencing of peptide fragments was done on the Micromass Q-Tof 
Micro mass spectrometer with data-directed acquisition (DDA). The MS to MS/MS switch 
criteria allowed a precursor selection of a maximum of 4 concurrent ions when the ion intensity  
was above a threshold of 10 ion counts per second.  To induce collisional activation, the collision 
energy was set at 25 V and argon was used as a collision gas at a pressure of 28 psi. 
 MALDI-TOF MS. To prepare the CHCA matrix, a total of 10 mg of α-cyano-4-
hydroxycinnamic acid was dissolved in 1 mL of water-acetonitrile (50 : 50, v/v) containing 0.1% 
trifluoroacetic acid.  A total of 5 µL of the matrix was mixed with 5 µL of a ten-fold dilution of 
the peptide hydrolysis reaction and with 1 µL of an internal standard (1.5 uM human synthetic 
angiotensin I).  A total of 1 µL of the resulting solution was transferred to a MALDI sample 
stage and air-dried.  Positive ion MALDI-TOF mass spectra were then acquired using an Applied 
Biosystems Voyager-DE PRO Biospectrometry instrument in reflectron mode.  Following time-
delayed extraction, ions were accelerated to 20 kV. A total of 500 laser shots was averaged for 
each mass spectrum.  The nitrogen laser source parameters included a grid voltage of 68.2%, a 
guide wire voltage of 0.001%, and a delay time of 50 ns. The average difference between 
calculated and observed mass values was m/z 0.044 ≤ 0.061. 
 Software.  All mass spectral peptide hydrolysis product peak assignments were made 
using FindPept software (The Swiss Institute of Bioinformatics; 
http://ca.expasy.org/tools/findpept.html).  The majority of the peak assignments was 
subsequently confirmed by HPLC-ESI-MS/MS sequencing (Tables 2.1 and 2.2). Isotope 
distribution patterns were predicted using the “Isotope Distribution Calculator and Mass Spec 
Plotter” (Scientific Instrument Services, Inc.; http://www2.sisweb.com/mstools/isotope.htm). 
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MS/MS fragmentation patterns were predicted with MassLynx/Biolynx software, version 4.0 
(Micromass). 
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information. 
Additional experimental details. 
Materials.  Distilled, deionized water was utilized in the preparation of all buffers and all 
aqueous reactions. Chemicals were of the highest available purity and were used without further 
purification. L-glutamic acid, α-cyano-4-hydroxycinnamic acid (CHCA), human synthetic 
angiotensin I, and oxidized bovine insulin chain B were purchased from Sigma. 
Ethylenediaminetetraacetic acid disodium salt (EDTA) was from Fisher Scientific and HPLC 
grade acetonitrile was from Burdick & Jackson. All other reagents including 4,13-diaza-18-
crown-6 (1,4,10,13-tetraoxa-7,16 diazacyclooctadecane), formic acid, and ZrCl4 (purity >99.99 
%) were obtained from the Aldrich Chemical Company. 
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Representative HPLC-ESI mass spectra. As described in the accompanying 
manuscript, a total of 500 µM of oxidized bovine insulin chain B was treated with 10 mM ZrCl4 
in 20 mM 4,13-diaza-18-cown-6 from t = 4 h to t = 8 h at pH 7.0 and 60 °C.  Peptide hydrolysis 
products were then identified by HPLC-electrospray ionization mass spectrometry (HPLC-ESI 
MS).  Shown in Figures 2.4, 2.5, 2.6 are representative ESI mass spectra at HPLC elution times 
of 18.36 min, 23.54 min, and 31.70 min, respectively. 
Zirconium(IV)-assisted deamidation and lactamization reactions. 
Zirconium(IV)-assisted deamidation.  HPLC-ESI analyses of the ZrIV hydrolysis 
reactions detected the production of apparent trace quantities of the following three sets of 
chromatographically separable insulin chain B peptide fragments: B†(1) and B†(2); D†(1) and 
D†(2); and F†(1) and F†(2) (Table 2.1.). Fragments B†(1) at m/z 909.3, D†(1) at m/z 966.4, and 
F†(1) at m/z 1053.5 were all observed to have masses that were approximately one mass unit 
higher than the parent peptides B (Phe1 to Cys(SO3H)7, at m/z 908.3), D (Phe1 to Gly8, at m/z 
965.5), F (Phe1 to Ser9, at m/z 1052.5; Table 2.1.). This result indicated that B†(1), D†(1), and 
F†(1) could be deamidated forms of the starting material with either Asn3 or Gln4 being 
converted to α-Asp3, α-Glu4, or to the geometric isomers β-Asp and γ-Glu.1 Fragment B†(2) at 
m/z 910.3, D†(2) at m/z 967.4, and F†(2) at m/z 1054.4, were all approximately two mass units 
higher that the parent peptides B, D, and F. Therefore, B†(2), D†(2), and F†(2) were proposed to 
be doubly deamidated. We then employed ESI-MS/MS sequencing to demonstrate that the three 
sets of fragments were indeed produced by deamidation of parent peptides B, D, and F: in B†(1), 
D†(1), and F†(1), Gln4 in the corresponding parent was converted to Glu4; in B†(2), D†(2), and 
F†(2), Asn3 and Gln4 were deamidated to Asp3 and Glu4.  
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Figure 2.4.  HPLC-ESI mass spectrum at an HPLC elution time of 18.36 min. Oxidized bovine 
insulin chain B was treated with ZrIV/4,13-diaza-18-crown-6 for  t=8 h.  In the spectrum are the 
singly and doubly charged observed masses corresponding to insulin chain B hydrolysis 
fragment Phe1 to Cys(SO3H)7 (fragment B, Table 2.1.).  The spectrum was acquired in positive 
ion mode.  
 
 
 
Figure 2.5.  HPLC-ESI mass spectrum at an HPLC elution time of 23.54 min. Oxidized bovine 
insulin chain B was treated with ZrIV/4,13-diaza-18-crown-6 for t = 4.  In the spectrum are the 
doubly and triply charged observed masses corresponding to insulin chain B hydrolysis 
fragments Gly20 to Ala30 (fragment I, Table 2.1.) and Glu21 to Ala30 (fragment K, Table 2.1.).  
The spectrum was acquired in positive ion mode. 
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Figure 2.6.  Representative HPLC-ESI mass spectrum at an HPLC elution time of 31.70 min. 
Oxidized bovine insulin chain B was treated with ZrIV/4,13-diaza-18-crown-6 for t = 4 h.  In the 
spectrum are the doubly and triply charged observed masses corresponding to insulin B chain 
hydrolysis fragments Gly8 to Ala30 (fragment C, Table 2.1.) and Ser9 to Ala30 (fragment E, 
Table 2.1.).  The spectrum was acquired in positive ion mode. 
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 Figures 2.4, 2.5, and 2.6 show representative ESI spectra with singly- and doubly-
charged spectra of the major products.  Shown in Figure 2.7 are representative HPLC-ESI-
MS/MS spectra acquired from precursor ions at m/z 965.5 (Fragment D, HPLC elution time 
18.50 min), at m/z 966.4 (Fragment D†(1), HPLC elution time 19.82 min), and at m/z 967.4 
(Fragment D†(2), HPLC elution time 20.54 min). A side by side comparison of successive N-
terminal fragment ions b3 to b5 and of successive C-terminal fragment ions y4 to y6 confirms the 
deamidation patterns described above. Because peptide deamidation at neutral pH is associated 
with the formation of α-Asp and β-Asp in a 1:3 ratio and α-Glu and γ-Glu in a 1:1.7 ratio,1a-b  we 
propose that insulin chain B fragments B†(1) and (2), D†(1) and (2), and F†(1) and (2) are likely 
to consist of mixtures of geometric isomers. With respect to parent fragments B, D, and F, the 
MS/MS data consistently revealed preferential deamidation of Gln4 over Asn3. This result was 
initially unexpected, in light of the fact that the majority of literature reports have maintained that 
asparaginyl residues are more susceptible to hydrolytic deamidation under neutral conditions.2 
Notwithstanding, deamidation rates are influenced by primary, secondary, tertiary, and 
quaternary protein structures.3 Consistent with our results, glutamine deamidation has been 
shown to be accelerated by flanking carboxyl side histidine residues (i.e., His5 in oxidized 
bovine insulin chain B).4 
 Zirconium(IV)-assisted lactamization. In order to further substantiate that ZrIV is 
capable of promoting lactamization in the presence of 4,13-diaza-18-crown-6, a total of 2 mM of 
glutamate was reacted in the presence of 20 mM of the azacrown ether, with and without 10 mM 
of ZrCl4. After 24 h of treatment at pH 7.0 and 60 °C, significant conversion of Glu (m/z 146.4) 
to pyroGlu (m/z 128.5) was observed in the reaction containing ZrIV/4,13-diaza-18-crown-6, and 
not in the reaction in which ZrIV was substituted by an equivalent volume of water (Figure 2.8.). 
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Figure 2.7.  Comparison of MS/MS spectra for Fragment D: Phe1-Gly8 and deamidation 
products. A total of 500 µM of oxidized bovine insulin chain B was treated with 10 mM ZrCl4 in 
20 mM 4,13-diaza-18-crown-6 for t = 8 h at pH 7.0 and 60 °C.  The MS/MS spectra show N-
terminal b-ions and C-terminal y-ions generated from m/z 965.5 (Fragment D: Phe1-Gly8), from 
m/z 966.4 (Fragment D‡(1): Gln4 in D converted to Glu4) and from m/z 967.4 (Fragment D‡(2): 
Asn3 and Gln4 in D converted to Asp3 and Glu4).  The m/z values in bold are rounded to the 
nearest Da.  The spectra were acquired in positive ion mode. 
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Figure 2.8.  ESI mass spectra of glutamate treated at pH 7.0 and 60 °C. (a) & (b): A total of 2 
mM of Glu was reacted with 10 mM of ZrCl4 in the presence of 20 mM 4,13-diaza-18-crown-6 
for 0 h and 24 h, respectively. (c) & (d): A total of 2 mM of Glu in 20 mM 4,13-diaza-18-crown-
6 was treated for 0 h and 24 h, respectively (no ZrCl4). “Glu” identifies glutamate; “pyroGlu” 
identifies pyroglutamate. The spectra were acquired in negative ion mode. 
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Table 2.1.  HPLC-ESI-MS analysis of peptides observed after oxidized bovine insulin chain B 
was reacted in the presence of ZrCl4 and 4,13-diaza-18-crown-6 (pH 7.0 and 60 °C) 
Peak 
assignment 
Elution 
time 
(min) 
Relative 
abundance 
HPLC (%) 
m/z singly charged 
peptide 
m/z doubly charged m/z triply charged 
 
 t = 4h t = 8h obsd calcd obsd calcd obsd calcd 
A: 
Phe1 to Ala30 
33.82 100 100 no 3494.7 1747.8 1747.8 1165.5* 1165.6 
B: 
Phe1 to Cys(SO3H)7 
18.36 11 50 908.3* 908.4 454.6 454.7 no 303.5 
B†(1): 
Gln4→Glu4 
19.73 2 3 909.3* 909.4 455.1 455.2 no 303.8 
B†(2): 
Asn3→Asp3, Gln4→Glu4 
20.46 2 3 910.3* 910.4 455.6 455.7 no 304.1 
C: 
Gly8 to Ala30 
31.70 12 7 no 2605.3 1303.0 1303.1 869.1* 869.1 
D: 
Phe1 to Gly8 
18.50 11 50 965.5* 965.4 483.2* 483.2 322.7 322.5 
D†(1): 
Gln4→Glu4 
19.82 2 3 966.4* 966.4 483.6 483.7 no 322.5 
D†(2): 
Asn3→Asp3, Gln4→Glu4 
20.54 2 3 967.4* 967.4 484.2 484.2 no 323.1 
E: 
Ser9 to Ala30 
31.70 12 7 no 2548.3 1274.5 1274.6 850.0* 850.1 
F: 
Phe1 to Ser9 
18.74 11 50 1052.5* 1052.5 526.7 526.7 351.7 351.5 
F†(1): 
Gln4→Glu4 
19.99 2 3 1053.4* 1053.4 527.2 527.2 no 351.8 
F†(2): 
Asn3→Asp3, Gln4→Glu4 
20.67 2 3 1054.4* 1054.4 527.7 527.7 no 352.1 
G: 
His10 to Ala30 
31.70 12 7 no 2461.2 1231.0* 1231.1 821.0 821.1 
H: 
Phe1 to Cys(SO3H)19 
33.79 5 5 no 2241.0 1121.0 1121.0 748.0 747.7 
I: 
Gly20 to Ala30 
23.54 9 44 1272.5 1272.6 636.8* 636.8 424.8 424.9 
J: 
Phe1 to Gly20 
33.79 5 5 2298.2 2298.1 1149.4 1149.5 766.7* 766.7 
K: 
Glu21 to Ala30 
23.54 9 44 1215.5 1215.6 608.3* 608.3 405.8 405.9 
K‡: 
Glu21→pyro(Glu21) 
26.48 3 16 1197.5* 1197.6 599.3* 599.3 400.1 399.9 
L: 
Phe1 to Leu6 
17.00 6 15 756.4* 757.4 378.6 379.2 no 253.1 
M: 
Leu6 to Tyr16 
28.11 1 4 no 1252.6 627.9 626.8 418.5 418.2 
a(oxidized bovine insulin chain B)0 = 0.5 mM; [ZrCl4]0 = 10 mM; [4,13-diaza-18-crown-6]0 = 20 mM.  Data were acquired over 
multiple trials.  Representative HPLC chromatograms are in Figure 2.4, 2.5, and 2.6. of the accompanying manuscript.  Peak 
assignments highlighted in blue correspond to apparent major peptide hydrolysis products.  Peak assignments in red correspond 
to apparent intermediate peptide hydrolysis products.  Peak assignments in green correspond to apparent trace peptide hydrolysis 
products.  Not observed = no. “*” indicates that peak assignments were confirmed by ESI-MS/MS sequencing. “†” indicates 
deamidation of peptide: Asn3 to Asp3 and/or Gln4 to Glu4. “‡” indicates lactamization of N-terminal Glu21 to pyroglutamate21 
(pyroGlu21). 
47 
 
Continued Table 2.1.:  HPLC-ESI-MS analysis of peptides observed after oxidized bovine 
insulin chain B was reacted in the presence of ZrCl4 and 4,13-diaza-18-crown-6 (pH 7.0 and 60 
°C) 
 
Peak 
assignment 
Elution 
time (min) 
Relative 
abundance 
HPLC (%) 
m/z singly charged 
peptide 
m/z doubly charged m/z triply charged 
 
 t = 4h t = 8h obsd calcd obsd calcd obsd calcd 
N: 
Gly8 to Cys(SO3H)19 
29.70 1 1 1351.8 1351.7 676.3* 676.3 no 451.2 
O: 
Gly8 to Gly20 
29.82 3 4 1408.6 1408.7 704.8 704.8 470.2 470.2 
P: 
Ser9 to Cys(SO3H)19 
30.39 1 no 1294.5 1294.6 647.7 647.8 432.5 432.2 
Q: 
Ser9 to Gly20 
28.11 1 1 1351.8 1351.7 676.3* 676.3 451.5 451.2 
R: 
His10 to Cys(SO3H)19 
33.40 2 2 1207.7 1207.6 604.73 604.3 403.5 403.2 
S: 
His10 to Gly20 
27.90 1 1 1264.5 1264.6 632.8 632.8 422.5 422.2 
T:  
His10 to Lys29 
29.61 1 1 no 2390.2 1195.4 1195.6 797.4 797.4 
U: 
Val2 to Ala30 
33.51 1 1 no 3347.6 1674.3 1674.3 1116.4 1116.5 
V: 
Leu11 to Ala30 
33.79 1 1 no 2324.2 1162.5* 1162.6 775.4 775.4 
W: 
Gly23 to Ala30 
25.82 6 25 930.5* 930.5 465.6 465.7 no 310.8 
X: 
Phe24 to Ala30 
24.19 3 13 873.3* 873.4     437.1 437.1 no 291.8 
a(oxidized bovine insulin chain B)0 = 0.5 mM; [ZrCl4]0 = 10 mM; [4,13-diaza-18-crown-6]0 = 20 mM.  Data were acquired over 
multiple trials.  Representative HPLC chromatograms are in Figure 2.4, 2.5, and 2.6 of the accompanying manuscript.  Peak 
assignments highlighted in blue correspond to apparent major peptide hydrolysis products.  Peak assignments in red correspond 
to apparent intermediate peptide hydrolysis products.  Peak assignments in green correspond to apparent trace peptide hydrolysis 
products.  Not observed = no. “*” indicates that peak assignments were confirmed by ESI-MS/MS sequencing. “†” indicates 
deamidation of peptide: Asn3 to Asp3 and/or Gln4 to Glu4. “‡” indicates lactamization of N-terminal Glu21 to pyroglutamate21 
(pyroGlu21). 
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Table 2.2.  MALDI-TOF MS analysis of peptides observed after oxidized bovine insulin chain B 
was reacted for 4.2 h in the presence of ZrCl4 and 4,13-diaza-18-crown-6 (pH 7.2 and 60 °C) 
 
Peak assignment Relative 
abundance MS 
(%) 
m/z singly charged 
peptide 
m/z doubly charged 
peptide 
t = 4.2 h obsd calcd obsd calcd 
A: 
Phe1 to Ala30 
22 3494.65 3494.65 1747.81 1747.83 
C: 
Gly8 to Ala30 
18 2605.21 2605.28 no 1303.14 
E: 
Ser9 to Ala30 
54 2548.16 2548.26 no 1274.63 
G: 
His10 to Ala30 
21 2461.13 2461.22 no 1231.11 
I: 
Gly20 to Ala30 
30 1272.63 1272.64 no 636.82 
K‡: 
(Glu21→pyroGlu21) 
100 1197.60* 1197.61 no 599.31 
M: 
Leu6 to Tyr16 
1 1252.68 1252.59 no 626.80 
T: 
His10 to Lys29 
1 2390.12 2390.19 no 1195.60 
U: 
Val2 to Ala30 
3 3347.48 3347.58 no 1674.29 
V: 
Leu11 to Ala30 
1 2324.08 2324.16 no 1162.58 
a[oxidized bovine insulin chain B]0 = 1 mM; [ZrCl4]0 = 10 mM; [4,13-diaza-18-crown-6]0 = 20 
mM.  Data were acquired over multiple trials.  Representative MALDI-TOF mass spectra are 
in Figure 2.3 of the accompanying manuscript.  Peak assignments highlighted in blue 
correspond to apparent major peptide hydrolysis products.  Peak assignments in red correspond 
to apparent intermediate peptide hydrolysis products.  Peak assignments in green correspond to 
apparent trace peptide hydrolysis products.  Not observed = no. “*” indicates that peak 
assignments were confirmed by ESI-MS/MS sequencing. “‡” indicates lactamization of N-
terminal Glu21 to pyroglutamate21 (pyroGlu21). 
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Epilogue. 
Deamidation of a dipeptide by ZrIV metal.  
   Deamidation results in the formation of glutamate from glutamine residues or aspartate 
from asparagine residues by hydrolysis. The deamidated products may also include geometric 
isomers such as iso-Glu and iso-Asp.1a-b  In addition to ZrIV, a number of metal ions, including 
CeIII, CeIV, LaIII,  and ThIV, are known to promote deamidation of glutamine to glutamate and of 
asparagines to aspartate.2  As mentioned previously, side reaction of zirconium hydrolysis in our 
data is deamidation of Asn3 and/or Gln4 residues in those hydrolysis products of insulin chain B 
which contained the two residues including the products Phe1-Cys(SO3H)7 (m/z 906), Phe1-
Gly8 (m/z 965), and Phe1-Ser9 (m/z 1052). (Figure 2.1, Table 2.1) which all showed minor +1 
and +2 Da analogs which were chromatographically separable by HPLC.  The MS/MS spectra 
also contained some Asn- and Gln-containing fragments which had a +1 and +2 Da shift.   
In order to confirm that ZrIV promotes deamidation of glutamine in the presence of 4,13-
diaza-18-crown-6, a total of 2 mM of the dipeptide GlyGln was reacted in the presence of 20 
mM azacrown ether, with and without 10 mM of ZrCl4 as shown in Figure 2.9. A similar 
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experiment was performed with the single amino acid Gln (data now shown). After 36 h of 
treatment at pH 7.0 and 60 °C, significant amounts of the hydrolyzed glutamine (m/z 147.1) was 
converted to the deamidated glutamate (m/z 148.1) product as observed in the reaction containing 
ZrIV / 4,13-diaza-18-crown-6 and not in the reaction where ZrIV was omitted. The absence of 
deamidated glutamine from the single amino acid glutamine indicates that internal peptide 
cleavage produces the deamidated product.  Glutamine presumably deamidates through a 
glutarimide intermediate while asparagine deamidates through a succinimide intermediate. 
References. 
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51 
 
 
 
            
 
 
Figure 2.9.  ESI mass spectra show deamidation of glutamine hydrolysis product to glutamate 
only in the presence of ZrIV and azacrown ether (left). Spectra a) and b): 2 mM GlyGln was 
reacted with 10 mM ZrIV and 20 mM azacrown ether for 0 h and 36 h, respectively (60 °C and 
pH 6.90).  Spectra c) and d): 2 mM GlyGln was reacted with 20 mM azacrown ether (no metal) 
for 0 and 36 h, respectively (60 °C and pH 7.15). Spectra were acquired in positive ion mode. 
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CHAPTER III    METAL-ASSISTED HYDROLYSIS OF SPHINGOMYELIN. 
 
Abstract. 
 
Niemann-Pick diseases types A and B are incurable lysosomal storage disorders caused 
by defective activity of the lysosomal enzyme acid sphingomyelinase, whose normal role is to 
hydrolyze the phospholipid sphingomyelin. In the severe phenotype A, there is a lethal build-up 
of sphingomyelin within the lysosomes of affected patients, with death by age 1 or 2 years.1  We 
have demonstrated that ZrIV complexes can hydrolyze the phosphate ester bond in 
sphingomyelin, and may possibly be developed as possible therapeutic tools in the treatment of 
Niemann-Pick disease, since ZrIV complexes have the potential to mimic acid sphingomyelinase.  
ZrIV hydrolysis of the phosphate ester bonds in sphingomyelin has been characterized by an 
assay that quantifies phosphocholine, which is the same proteolytic product produced by the 
active enzyme. Since the highest hydrolytic yields of DNA2 and acetylated peptides3 by ZrIV is 
lysosomal pH 4.8 compared to cytosolic pH 7.0, we would like to develop phospholipid 
hydrolysis protocols to confirm that ZrIV complexes hydrolyze sphingomyelin more efficiently at 
pH 4.8 and 37 °C than pH 7. We have found that ZrIV in the presence of piperazine hydrolyzes 
sphingomyelin in good yields at 60 °C and pH 4.8 within 20 h. Since the amphiphilic 
sphingomyelin molecule exists physiologically in liposomes with bilayer structures, we have 
conducted Triton X-100 liposome-micelle transition studies and characterization protocols based 
on atomic force microscopy and UV-visible spectrophotometry to observe the effect of liposome 
solubilization. The effects of micelle formation by addition of Triton X-100 surfactant have been 
evaluated to increase the efficiency of metal-assisted phospholipid hydrolysis as a function of 
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temperature and pH. Also, the effect of membrane-bound cholesterol on hydrolysis yields has 
been investigated. We have demonstrated that zirconium hydrolyzes the phosphate ester bonds in 
two colorimetric assays which measure either free phosphate or phosphocholine/choline 
concentrations. Metals used by other researchers to hydrolyze unactivated amide and phosphate 
ester bonds 4-16 have been used to hydrolyze sphingomyelin for comparison to ZrIV.  These metals 
include CuII, CoII, CeIV, EuIII, NiII, PdII, LaIII, YIII, YbIII, and ZnII.  For each metal, we have 
examined the increase in hydrolysis at lysosomal pH 4.8 compared to the cytosolic pH 7.0.  
Introduction. 
Metal-assisted hydrolysis of phospholipids. 
Metals have been demonstrated to be effective reagents in the hydrolysis of the phosphate 
ester bond of substrates such as nucleic acids, synthetic phospholipids, and phosphorylated 
sugars.  Metals, particularly lanthanide, actinides, rare earth, and tetravalent transition metals are 
excellent hydrolytic reagents because of their dual ability to neutralize the phosphate anionic 
charge and to provide a nucleophile using their deprotonated bound waters of hydration.4-16  
Figure 3.1 ranks the metals used in this study with their respective hydrolysis constants (pKa) of 
the water-bound metal species. The tetravalent metal ions CeIV, ZrIV, HfIV, and divalent PdII 
lower the pKa of water from 15.7 to < 2 and, thereby, form metal-hydroxide species when 
dissolved in aqueous hydrolysis reactions at pH 4.8 or 7.17-20  The metal ion zirconium(IV) has 
been found to efficiently hydrolyze amide bonds in peptides.21 ZrIV also hydrolyzes phosphate 
ester bonds in a synthetic p-nitrophenol activated phosphate ester.7,9,10,11,13,15 According to these 
studies, cleavage levels were substantially increased when the reaction pH was changed from 7.0 
to more acidic pH values in the range of 4.0-4.7, which is near the lysosomal pH of 4.8. 
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The metal-assisted hydrolysis of the phosphate ester bond of biological phospholipids 
involved in cell membrane structures is a novel approach to the development of therapeutic drugs 
for use in the incurable lysosomal storage disease of Niemann-Pick disease A and B.  These 
disorders produce a lethal build-up of sphingomyelin in liver, spleen, and brain cells due to the 
defective lysosomal acid sphingomyelinase enzyme.  Selected metals were used in the present 
study to represent a range of cellular toxicities, and selectivity toward the phosphate ester bond 
in synthetic phospholipids and human phospholipids.7,11 The pH of the lysosomal interior is pH 
4.8, and is thus considerably more acidic than the cytoplasm (pH 7.2). It is worthwhile to 
investigate the pH-dependent reactivities of metals to estimate the increase in metal-assisted 
hydrolytic cleavage of sphingomyelin in the lysosomes compared to cytosol. ZrIV is of particular 
interest due to its low cellular toxicity and lack of natural metalloenzyme activity interference in 
humans.22a-o The optimal hydrolysis of DNA and acetylated peptides by ZrIV has been shown to 
be higher at (lysosomal) pH 4.8 than (cytosolic) pH 7.0.2-3 Table 3.1 shows various pH values 
which are relevant to optimal ZrIV activity and lysosomal pH. The lysosomal pH is not only the 
optimal pH of the acid sphingomyelinase enzyme which is defective in Niemann-Pick patients, 
but is also approaching the optimal pH of ZrCl4 activity in the hydrolysis of acetylated Gly-Gly.2 
There is strong motivation to use ZrIV and similar metals as therapeutic agents to target disease-
related, lysosomal phospholipids such as sphingomyelin. 
Sphingomyelin.   
Sphingomyelin is a major phospholipid in animal plasma membranes and predominates 
in the human brain, the myelin sheath of nerve cell axons, and in erythrocytes. It consists of a 
phosphate group, sphingosine, choline, and an N-acyl linked fatty acid. The fatty acid content of 
sphingosine and the N-acyl linked fatty acid varies, but palmitic (16:0), stearic (18:0) and 
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nervonic acids (24:1) are the most abundant in humans. Approximately 60 % of the fatty acids of 
of the sphingomyelin of the grey matter of the human brain consist of stearic acid (18:0) while 
60 % of the corresponding sphingomyelin in the white brain matter consist of lignoceric (24:0) 
and nervonic (24:1) acids.     Human sphingomyelin interdisperses with phosphatidylcholine and 
cholesterol in the exoplasmic layer of the plasma membrane lipid bilayer.  The fatty acids which 
predominate in sphingomyelin of plasma membranes are more saturated than 
phosphatidylcholine.  The sphingosine-bound fatty acid is typically longer than the N-acyl linked 
fatty acid moiety which introduces length assymetry.23-24 Figure 3.2 shows the structure of 
sphingomyelin along with two possible hydrolysis products of phosphocholine and choline. 
Figure 3.3 shows the structures of piperazine and HEPES which are the buffers used in the 
hydrolysis reactions described in this dissertation since their pKa values corresponded to 
lysosomal pH 4.8 or to cytosolic pH 7, respectively.  Figure 3.4 shows the polar and nonpolar 
regions of sphingomyelin along with the two possible metal-assisted hydrolytic pathways which 
produce either phosphocholine or choline. Sphingomyelin is capable of both intra- and inter-
molecular bonding. The amide group’s nitrogen and the hydroxyl on the sphingosine moiety are 
hydrogen donor sites, while the amide carbonyl oxygen provides a hydrogen acceptor site. 
Intramolecular bonding occurs between the free hydroxyl on the sphingosine base and the 
phosphate ester oxygen. Intermolecular bonding arises from van der Waals forces between the 
hydrocarbon chains and cholesterol which associates with sphingomyelin in membranes. The 
intermolecular bonding is decreased in the case of the trans double bond in the nervonic acid 
fatty acid. The configuration of human sphingomyelin is the enantiomerically pure form of D-
erythro with two chiral centers formed by the sphingosine free hydroxyl (C3) and the amide NH2 
(C2) groups in the 2S, 3R configuration. 
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Figure 3.1.  Deprotonation of the waters of hydration on selected metal ions. Encircled metals 
demonstrate the highest hydrolysis yields in metal-assisted hydrolysis of phospholipids as 
discussed in this chapter.The pKa data were taken from Metal Ions in Solution, 1978, p. 356 by 
John Burgess.17 
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Table 3.1.  The correlation of biological pH values to optimal pH of ZrIV-assisted hydrolysis. 
 
Cellular location or experiment Optimal pH 
Lysosome   pH 4.8 
Cytosol   pH 7.2 
Optimal activity of acid sphingomyelinase   pH 4.8 
  (inactive at pH 7.0) 
Maximum reactivity of 20 mM ZrCl4 hydrolysis of DNA at 20 °C 2   pH 4.0 
Optimal activity of ZrIV-assisted hydrolysis of AcGG at 37 °C, 45 °C, 
and 60 °C 3 
 
  pH 4.4 
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Figure 3.3.  The molecular structures of the buffers used in our hydrolysis experiments: (a) 
piperazine (lysosomal pH 4.8); (b) HEPES (cytosolic pH 7). The piperazine and HEPES 
structures show the protonation site responsible for the pKa values.40 
Figure 3.2.  (a) Structure of sphingomyelin; (b) structure of phosphocholine; (c) structure of 
choline. 
(a) 
(b) (c) 
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Figure 3.4.  Diagram of the metal-assisted phosphate ester bond hydrolysis of sphingomyelin to 
either phosphocholine or choline products. The sphingomyelin structure contains a polar 
headgroup and a non-polar hydrophobic tail.  
                                            
Hydrophobic Tails = Sphingosine + N-acyl Linked Fatty Acid = Ceramide Polar Headgroup  =  Choline + PO4 - 
Hydrolysis pathway of acid 
sphingomyelinase 
Alternate hydrolysis 
pathway 
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         The acyl chain composition of sphingomyelin determines the gel to liquid-crystalline phase 
transition temperature and the enthalpy of transition. The gel to liquid-crystalline phase transition 
for pure sphingomyelin is the physiological temperature of 37 °C. The transition temperature is 
governed by phosphocholine head group repulsion and hydrocarbon chain packing. 23-31  
Cholesterol is closely associated with sphingomyelin in amounts up to 45 mol % in 
normal cell membranes, but accumulates to a much higher percentage in Niemann-Pick diseased 
cells. It controls membrane fluidity by restricting acyl chain motion and reduces permeability of 
the membrane. The cholesterol molecule consists of a polar hydroxyl group which hydrogen 
bonds with the polar head of sphingomyelin and a nonpolar sterol center and a hydrocarbon 
chain of 7 carbons which are embedded in the nonpolar fatty acid tails of the inner 
sphingomyelin bilayer.23-24 The addition of 30 mol % of cholesterol to sphingomyelin eliminates 
the gel-to-liquid crystalline phase transition.28 Cholesterol also increases the detergent resistance 
of sphingomyelin in plasma membranes.27 
In normal cells, sphingomyelin exists physiologically as liposomes. However, the 
speciation of sphingomyelin in Niemann-Pick disease is unknown. Therefore, the incorporation 
of Triton X-100 to solubilize the normal vesicle structures was undertaken.  Triton X-100 is a 
nonionic surfactant commonly used to solubilize phospholipid vesicles in many studies in order 
to induce a transition from vesicles to micelles with intermediate mixed populations.32a-k   Figure 
3.5 shows the transition envisioned by Lopez et al.32f  with five stages: pure vesicles, enlarged 
vesicles with interdispersed Triton X-100, saturated bilayered vesicles plus detached micelles for 
a mixed population,  a predominate micellar population with few saturated bilayers, and, finally, 
a population consisting of exclusively micelles with sphingomyelin interdispersed with Triton X-
100.  
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Figure 3.5.  Schematic of Triton X-100 induced phospholipid vesicle to micelle transition, Lopez 
et al, FEBS Letters, 1998,32f shown along with the structure of Triton X-100. The ethylene oxide 
units have n = 9.5 according to manufacturer label. 
Increasing Triton X-100 amounts 
= 9.5 
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In the in vivo enzymatic reaction of acid sphingomylinase, the hydrolysis of 
sphingomyelin occurs at the phosphate ester bond between the phosphocholine and sphingosine 
to release phosphocholine and a ceramide as shown in Figure 3.4. In order for metal-assisted  
hydrolysis to mimic the enzyme, the metal will be oxophilic and a hard Lewis acid in order 
toactivate the phosphate ester bond.  Ideally as an enzyme mimic, the hydrolysis reaction should 
be regioselective and cleave only one side of the phosphate ester. Tetravalent metals such as 
ZrIV, CeIV, and HfIV are oxophilic with high charge density and, as we show, are capable of 
hydrolyzing the phosphate ester bond of sphingomyelin to yield a phosphocholine and a 
ceramide. If the metals lack regioselectivity, the hydrolysis will produce a choline and 
phosphoceramide.  
Niemann-Pick disease.   
  Niemann-Pick disease (NPD)33a-i is an incurable, autosomal recessive, lysosomal storage 
disorder with two phenotypes A and B. Type A primarily affects Ashkenazic Jews with infant 
mortality while type B affects other diverse ethnic groups with middle age mortality. The NPD 
forms A and B result from over 18 mutations on the acid sphingomyelinase gene in chromosome 
11, and both types A and B are associated with very low acid sphingomyelinase activity 
compared to the wild type.  Approximately 80 % of NPD patients are Type A. The majority of 
the Type A patients of European Jewish ancestry have a 1:90 type A gene carrier rate and 
1:30,000 physical disease occurrence. The defective enzyme acid sphingomyelinase has only 1-
3% normal activity in type A while type B has 10-60 % of normal enzyme activity, and both 
result in fatal accumulation of sphingomyelin in the lysosomes. Based on the autopsies of 
Niemann-Pick patients in several studies, sphingomyelin accumulated in the spleen is 15 - 99 
µmol of sphingomyelin per g of wet tissue compared to the control spleens at 2 - 4 µmol per g of 
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wet tissue.33a-b The affected organs in type A are the spleen, lymph nodes’ monocyte-
macrophage system, liver, kidneys, brain, and lung, while type B has similar patterns except for a 
lack of accumulation in the brain.  Cholesterol also builds up in the lysosomes, most probably 
due to the interdispersion of cholesterol with sphingomyelin in the periplasmic membrane. 
Enzyme replacement and chemical chaperones have had limited therapeutic success in treating 
Niemann-Pick patients.33a-i  A novel therapeutic cure based on ZrIV-assisted phospholipid 
hydrolysis is the concept developed in this dissertation.  This approach would serve to decrease 
this fatal accumulation of sphingomyelin in NPD patients. Since ZrIV is redox-inactive and 
possesses low cellular toxicity, a ZrIV complex which efficiently hydrolyzes sphingomyelin at the 
same hydrolytic bonds and pH values as the acid sphingomyelinase enzyme may function as an 
enzymatic mimic.   
Methods. 
Purchases.  
 All metals were purchased from Sigma-Aldrich and all had a purity of 99.999% except 
for  potassium tetrachloropalladate(II) (K2PdCl4) and europium(III) chloride hexahydrate (EuCl3-
6H2O) (99.99%), hafnium(IV) tetrachloride (HfCl4) (98%), and bis(cyclopentidienyl) 
zirconocene(IV) dichloride (C10H10Cl2Zr) (>98%).  Metal hydrolytic activity was assayed on 
vesicles composed of pure sphingomyelin without and with cholesterol. Porcine brain 
sphingomyelin was purchased from Avanti Polar Lipids (860062P) and was used without further 
purification. The sphingomyelin has a reported gel-liquid transition temperature at ca. 35 °C and 
is a heterogeneous mixture of 18:0 stearic acid (49%), 24:1 nervonic acid (20%), and 31% 
various (16:0, 20:0, 22:0, 24:0, and other) fatty acid composition.34 Observed MALDI mass 
peaks of the sodium adducts at m/z 753 and m/z 835 correlate to the stearic and nervonic fatty 
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acid content.  Triton X-100 solution (93443) was purchased from Fluka BioChemika. HEPES 
sodium salt (H7006) was purchased from Sigma-Aldrich, and piperazine anhydrous buffer 
(80621) was purchased from Fluka. Cholesterol (C8667) was purchased from Sigma in 99% 
purity. 
Metal-assisted hydrolysis.   
 The sphingomyelin liposomes were prepared by sonication as follows.  The 
sphingomyelin was dissolved in chloroform.  This solution was evaporated overnight to produce 
a dry film followed by 2 h of drying under vacuum. For cholesterol experiments, the dried 
sphingomyelin and cholesterol were dissolved together in chloroform and the solution 
evaporated by the same protocol. The dried sphingomyelin was hydrated to a concentration of 
100 mM in pre-heated doubly-deionized H2O at 55 °C, a temperature that is above the gel-liquid 
crystal transition temperature of sphingomyelin. The aqueous suspension was placed in a water 
bath and sonicated for 30 min (45 min for cholesterol experiments) to produce a milky 
suspension with a high surface tension.  These liposomes are assumed by definition to be small, 
unilamellar vesicles (SUVs) and were later examined by atomic force microscopy (AFM).  
Hydrolysis reactions of liposomes prepared from the stock sphingomyelin solution in 
1000  µl volumes contained a final concentration of 2 mM sphingomyelin, 10 mM metal and 20 
mM piperazine (pH 4.8) or HEPES (pH 7) buffer. The metals included period 4, 5, and 6 metals 
Ce(NH4)2(NO3)6, ZrCl4, HfCl4, K2PdCl4, CuCl2-2H2O, ZnCl2, CoCl2-H2O, NiCl2-6H2O, EuCl3-
6H2O, LaCl3-H2O, YCl3-6H2O, and YbCl3-6H2O. The metal and the buffer were premixed and 
pH-adjusted to 4.8 or 7.0 with HCl or NaOH prior to adding to the final volume of the diluted 
aqueous sphingomyelin stock solution. For solutions containing surfactant, the Triton X-100 was 
vortexed with the aqueous sonicated sphingomyelin solution at 25 °C and pre-equilibrated for at 
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least 30 minutes prior to the dilution and metal/buffer addition. The final Triton X-100 
concentrations were either 0, 2, or 16 mM.  Individual reactions were placed on an Eppendorf 
Thermomixer R preheated to 60 °C or 37 °C for 20 h at 500 rpm. 
Malachite green assay and turbidity.  
 A Quantichrom Phosphate Assay™ (Bioassay Systems, Inc.) was used to detect free 
inorganic phosphate.  A Shimadzu UV-1601 UV-visible spectrophotometer was used to record 
the absorbance at 620 nm with total acquisition in the 1100-300 nm range.39 The inorganic 
phosphate is released as a secondary cleavage product after sequential hydrolysis of both 
sphingomyelin phosphate ester bonds. This assay utilizes the complexation of molybdate and 
phosphate ions to form a heteropolyphosphomolybdate complex which is subsequently bound by 
the dye malachite green.39 The malachite green assay utilized 25 µL for ZrIV (3 µL for CeIV 
samples) samples, 142 µL for ZrIV (164 µL for CeIV) H2O, and 333 µL malachite green assay 
reagent for a total volume of 500 µL. The solutions were vortexed after each addition, and 
spectrally analyzed after 30 min.  Positive controls of phosphocholine and choline that were 
prepared and reacted with similar metal/buffer concentrations at 60 ±C for 20 h were used to 
determine statistical accuracy of the assay.   
In order to correct for background levels of inorganic phosphate, the absorbance 
differences at both 0 h and 20 h for all of the metal reactions and for parallel control reaction 
ions run in the absence of metal were measured.  Histograms were developed by subtracting the 
absorbance difference (20 h – 0 h) in the absence of metal from the absorbance difference (20 h – 
0 h) in the presence of metal to yield a background-subtracted absorbance difference that 
represents phosphate released only from the metal-assisted reaction. 
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Standard curves.  
  A series of solutions of increasing phosphate concentration and a constant 10 mM metal 
and 20 mM buffer concentrations as the assayed hydrolysis samples were prepared in the 
absence of Triton X-100 in order to quantify the malachite green assay results and assess 
experimental metal interference with the molybdenum-phosphate-malachite green assay. Parallel 
non-metal control phosphate standards containing only 20 mM buffer were also measured. 
Solutions of 100 mM metal and 200 mM piperazine or HEPES buffer were prepared and mixed 
1:1 v/v.  The premixed 1:1 metal/buffer solution was pH-adjusted to either 4.8 or 7.0 with either 
HCl or NaOH and heated at 60 °C for 20 h. The dilution of 25 µL of a typical hydrolysis reaction 
sample to 500 µL total volume in a malachite green assay represents a 20-fold dilution of the 
sample so the diluted standards were prepared with similar metal/buffer concentrations as the 
diluted hydrolysis sample. The 30 µM phosphate stock solution was included in the Quantichrom 
Phosphate Assay™ kit from which a total of 9 different phosphate concentrations were prepared 
in the range of 0-11 µM at a total volume of 500 µL each. The amount of 30 µM phosphate stock 
solution, premixed 1:1 metal/buffer solution to give a final solution of 0.5 mM metal/1 mM 
buffer concentration, doubly-deionized water were mixed first followed by addition of 333 µl 
malachite green reagent. The total volume was mixed thoroughly and allowed to equilibrate for 
30 minutes. In summary, the final concentrations of the standard solutions for all metals except 
cerium(IV) were 0, 1, 3, 5, 7, 8, 9, 10, 11 µM of inorganic phosphate in 0.5 mM metal, and 1 
mM buffer in a total volume of 500 µL with two exceptions in the highest standards of 10 and 11 
µM which each had 507 µL and 538 µL volumes. The two highest phosphate standards had a 
higher total volume (> 500 µL) in order to maintain the same malachite green reagent amount in 
all standard solutions. An example of a 5 µM phosphate standard would be prepared from 84 µL 
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of the 30 µM phosphate stock solution, 5 µL of the 1:1 metal/buffer solution, 78 µL doubly-
deionized water, and 333 µL malachite green reagent for a total volume of 500 µL. The cerium 
standards were prepared with similar procedures except the 1:1 metal/buffer solutions were 
diluted 10-fold, i.e. 5 mM cerium(IV) metal ion concentration and 10 mM buffer concentration 
at this step,  in water prior to addition to each standard because of the greater dilution of cerium 
reaction samples, e.g. 3 µL reaction sample instead of 25 µL diluted to 500 µL which is a 166.7-
fold dilution. The final metal and buffer concentrations in the cerium(IV) samples were 60 µM 
cerium(IV) metal ion and 120 µM buffer. The standards prepared for the non-metal control 
samples were prepared with the 30 µL stock phosphate solution, 200 mM buffer (final buffer 
concentration in standard is 1 mM), doubly-deionized water, and malachite green reagent for a 
total volume of 500 µL. The standards were analyzed on a Shimadzu UV-1601 instrument in the 
1100-300 nm range. The slope equations were determined from phosphate concentration plotted 
against absorbance at 620 nm and yielded linear slopes with correlation coefficients of r = 0.999.  
Turbidity measurements were conducted on the liposomes to gain additional insight into 
the vesicle to micelle transition. Solubilization with Triton X-100 was measured as a decrease in 
turbidity of the sphingomyelin vesicle suspensions at 500 nm absorbance. Turbidity was 
measured on 2 mM sphingomyelin in piperazine buffer at pH 4.8 without metal with increasing 
amounts of Triton X-100 (0-100 mM) on a Shimadzu UV-1601 spectrophotometer with 
acquisition in the range of 1100-300 nm. Data absorbance at 500 nm was plotted.   
Phosphocholine and choline quantification.    
              Phosphocholine and choline hydrolysis products were quantified with an Amplex Red 
Sphingomyelinase Assay kit (Invitrogen-Molecular Probes) which uses a multi-enzyme 
reaction series to produce H2O2 that reacts with the sensitive colorimetric Amplex Red 
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reagent.35 All enzymes were prepared according to the kit’s instructions and the two-step 
sphingomyelinase assay described in the kit was used since the lysosomal pH samples were in 
the acidic pH range. Figure 3.6 illustrates the conversion of the phosphocholine and/or choline 
substrates to a detectable product. The alkaline phosphatase enzyme converts phosphocholine to 
choline which is subsequently converted by choline oxidase to betaine and H2O2.  The H2O2 
substrate in the presence of horseradish peroxidase reacts with Amplex Red reagent to produce 
a red solution which was analyzed with a Shimadzu UV-1601 UV-visible spectrophotometer in 
the acquisition range 300-1100 nm with the absorbance at 570 nm recorded for quantification 
calculations.  Since both phosphocholine and choline were possible hydrolytic products, the 
results yielded the total phosphocholine and choline products from the hydrolysis reactions.  In 
order to distinguish the phosphocholine yields from the choline yields in the mixture, a novel 
adaptation of the assay was developed by preparation of a parallel, multi-enzymatic reaction 
series where the alkaline phosphatase enzyme was omitted to prevent any phosphocholine 
hydrolysis product from being enzymatically converted to choline. 
  Dual sets of phosphocholine or choline standards were prepared for quantification of the 
enzyme mixes with and without the alkaline phosphatase, respectively.  The stock solutions of 
phosphocholine and choline from which the standards were directly prepared were 100 mM 
concentration serially diluted in 100 mM Tris buffer, pH 8, to a substock concentration of 1 mM 
phosphocholine or choline in 100 mM Tris buffer with no metal or hydrolysis reaction buffer. 
Many reaction samples were diluted 10-fold for the Amplex Red assay so the phosphocholine 
and choline standards were prepared with 1 mM metal and 2 mM buffer final concentrations. 
The metal and piperazine or HEPES stock solution was prepared with a concentration of 100 
mM and 200 mM, respectively, and premixed in a 1:1 v/v solution with pH adjustment to pH 4.8 
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or 7 depending on the experiment. The 1:1 premixed metal/buffer solutions were heated at 60 °C 
for 20 h.  Amounts of the 1 mM phosphocholine or choline substock solution, 20 µL of the 1:1 
metal/buffer mix, and 100 mM Tris buffer, pH 8, were mixed for final phosphocholine or choline 
concentrations of 0.005, 0.01, 0.02, 0.05, 0.08, 0.1, and 0.2 mM with a final metal/buffer 
concentration of 1 mM metal and 2 mM buffer in a  total volume of 1000 µL for each standard.   
Each set included seven standards in the concentration range of 0 - 0.2 mM substrate and 
produced slope equations with correlation coefficients of ≥ 0.99 in the 0 - 0.1 mM linear range of 
the slope.  Amounts of these phosphocholine and choline standard sets were later mixed with the 
enzyme mix which is described below. 
 The enzyme mix stock solution components were prepared according to the kit’s 
protocols. The final enzyme mix for the total phosphocholine plus choline quantification 
included 100 µL horseradish peroxidase solution, 100 µL choline oxidase solution, 200 µL 
alkaline phosphatase solution, 100 µL Amplex Red reagent solution, and 9.5 mL of 100 mM 
Tris-HCl, pH 8.0. For the final enzyme mix for the choline-only assay, the amount of alkaline 
phosphatase was substituted with an equivalent volume of 100 mM Tris-HCl, pH 8. The enzyme 
mixes were used immediately without storage of the remaining, unused enzyme mix.  
 For the final assay sample preparations prior to the 37 °C incubation step, the following 
protocol was performed. The hydrolysis reaction samples were diluted between 10 to 50-fold 
with 100 mM Tris buffer, pH 8, in order to have absorbances in the linear standard range. For the 
final, enzymatic sample preparation using the Amplex Red enzyme mixture, 50 µL of diluted 
reaction sample or standard solution was mixed with 100 µL of either of the two enzyme mixes 
described above containing horseradish peroxidase, choline oxidase, and alkaline phosphatase, 
and the Amplex Red reagent. A second set of samples were prepared with the non-alkaline 
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phosphatase enzyme mix for the choline-only quantification.  Enzyme controls were prepared 
with an equivalent amount of doubly-deionized water plus enzyme mix. The solutions were 
gently stirred and placed in a 37 °C incubator for one hour. After one hour, the vials were placed 
in the freezer to quench the enzymatic reactions. Immediately prior to analysis, 400 µL of 
doubly-deionized water was added to each 150 µL sample, vortexed, and placed in a cuvette for 
spectral acquisition. All data was acquired within hours of the sample preparation. All assays 
were performed on the same day as the completion of the 20 h hydrolysis reactions.   
          Positive controls of phosphocholine and choline were prepared in a similar procedure as 
the metal-assisted sphingomyelin reaction samples. Stock solutions of 55.82 mM phosphocholine 
or 75.08 mM choline were prepared along with 100 mM metal and 200 mM piperazine or 
HEPES buffer solutions. The metal and buffer were premixed in a 1:1 v/v solution, and the pH 
was adjusted to pH 4.8 or 7 with HCl or NaOH.  All positive control samples were prepared with 
no Triton X-100 addition. The final concentrations of the metal-assisted phosphocholine or 
choline reaction samples were 1.12 mM and 1.49 mM, respectively, in 10 mM metal and 20 mM 
buffer concentrations. Positive controls of phosphocholine and choline were heated at 60 ±C for 
20 h similar to the hydrolyzed sphingomyelin reactions. The hydrolyzed samples were diluted 
50-fold in 100 mM Tris buffer, pH 8 prior to the Amplex Red assay to a final concentration of 
22.4 µM original phosphocholine or 29.8 µM original choline in 100 mM Tris buffer, pH 8 with 
diluted metal and buffer concentrations of 200 µM metal and 400 µM buffer. A total of 50 µL of 
each of the diluted positive control reaction samples was added to 100 µL of either of the two 
enzyme mixes containing the Amplex Red reagent and treated as described in the previous 
paragraph. 
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 For the phosphate determinations, the positive control samples of phosphocholine and 
choline were prepared according to the metal used in the hydrolysis reaction. If the sample was 
hydrolyzed with zirconium(IV) metal, then 25 µL volumes of the 1.12 mM phosphocholine or 
1.49 mM choline metal-assisted samples were added to 142 µL of doubly-deionized water and 
vortexed. If the sample was hydrolyzed with cerium(IV) metal, then 3 µL of the 1.12 mM 
phosphocholine or 1.49 mM choline metal-assisted samples were added to 164 µL doubly-
deionized water and vortexed. Next, 333 µL of the malachite green reagent was added to the 
diluted sample mix (all metals) and vortexed. The green colorimetric solution developed for 30 
minutes. Afterwards, the entire 500 µL volume was pipetted into a cuvette and spectrally 
analyzed over the wavelength range of 300-1100 nm and the absorbances at 620 nm were 
recorded. 
 Hydrogen peroxide positive controls were provided in the kit with the specific 
concentration on the label which was ~ 3 %. Only new, unopened vials were used for the 
controls since the hydrogen peroxide degrades quickly. Based on the precise concentration 
indicated on the vial, e.g., precisely 3.3%, a 20 mM working solution of H2O2 was prepared by 
dilution in doubly-deionized water. A second serial 10-fold dilution of this 20 mM H2O2 was 
prepared by dilution with doubly-deionized water for a final substock solution of 0.22 mM H2O2. 
From this substock solution, three different concentrations of 0.02, 0.04, and 0.06 mM were 
prepared and analyzed by either the total phosphocholine plus choline or the modified choline-
only protocols described above with 50 µL hydrogen peroxide samples and 100 µL enzyme mix 
with 1 h incubation at 37 °C. 
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Atomic force microscopy.   
  Atomic force microscopy (AFM) was used to study the liposome preparations with 
various amounts of Triton X-100 to determine the size and shape of the pure and solubilized 
vesicles.  Sphingomyelin vesicle suspensions equilibrated with 0, 2, or 16 mM Triton X-100 
were imaged by AFM as follows.  Aliquots of 10 µL were dried on mica substrates overnight and 
imaged by a Veeco Multi Mode V instrumentation at a rate of 2.5 µM/s. Imaged data was 
reviewed with Thermomicroscope SPMLab NT Ver. 5.01 software. The data included the image, 
histograms, and cross-sectional views from selected areas of the image. The histograms recorded 
the number of Z-heights from the probe to the nm-µm height range. 
Results and discussion. 
Liposome solubilization and turbidity.    
Solubilization of liposomes by a detergent such as Triton X-100 provides a good model 
for the solubilization of cell membranes. Triton X-100 is a nonionic detergent that has been used 
to study the ability of surfactants to alter phospholipid bilayer structures with subsequent 
conversion from vesicle to mixed micelle or pure micelle populations.  Triton X-100 causes a 
surfactant-dependent increase in phospholipid vesicle size as confirmed directly by light 
scattering and indirectly by an increase in turbidity of sphingomyelin preparations.32f A gradual 
increase in size with increasing Triton X-100 concentration and incorporation or interdigitation 
as noted by electron micrographs was observed parallel to the increase in turbidity in several 
studies.32a,c  In these studies, turbidity was measured by recording the absorbance at 500 nm. The 
turbidity curve in Figure 3.7 shows the millimolar concentrations of Triton X-100 and the 
sphingomyelin lipid : Triton X-100 molar ratio as plotted against the absorbance at 500 nm.  The 
liposomal sizes affect the transmittance of the beam as reflected an increase or reduction in  
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Figure 3.6.  Molecular Probes Amplex Red sphingomyelinase assay: detection of choline 
and phosphocholine products released upon metal-assisted hydrolysis of sphingomyelin.35 
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absorbance at 500 nm. The graphs show an increase in turbidity in the Triton X-100 range of 1-3 
mM (less than 1: 2 phospholipid: Triton X-100 ratio) with a sharp decline in the turbidity with 
higher (> 3 mM) Triton X-100 concentrations.  The sample appearance correspondingly changed 
from cloudy to transparent over this concentration range.  
These trends are postulated to correspond to the incorporation of Triton X-100 into the 
vesicle structures with a resulting increase in size, and thus turbidity (1-3 mM Triton X-100 
range of the curve) while the regionof negligible absorbance levels correspond to micelle 
formation (≥ 5 mM Triton X-100).According to Figure 3.5, the incorporation of Triton X-100 
involves several stages of vesicle incorporation of Triton X-100 with accompanying increase in 
size and turbidity until saturation followed by subsequent transformation into breakaway 
micelles with decreased size and turbidity. The Triton X-100 concentrations of 0, 2, and 16 mM 
used in the hydrolysis represent distinctly different liposomal populations with pure vesicles (0 
mM), mixed vesicle/micelle (2 mM), and pure micelles (16 mM). When cholesterol is added in 
50 mol % of sphingomyelin, the turbidity pattern in Figure 3.8 shows an initial increase in 
turbidity which increases slightly over the entire Triton X-100 concentration range of 5-100 mM. 
Cholesterol increases resistance of sphingomyelin to solubilization as evidenced by the increased 
turbidity even at very high Triton X-100 amounts.32j  Tighter packing of sphingomyelin’s fatty 
acid chains, which is induced by cholesterol, has been attributed to this resistance to detergent 
solubility.27 Additionally, cholesterol is hydrophobic and will aggregate in solution. The 
persistent increase in turbidity of the sphingomyelin liposomes prepared with 50 mol % 
cholesterol over the entire Triton X-100 concentration range is consistent with the observed 
solution cloudy appearance compared to solutions without cholesterol which become clear 
(decrease in turbidity) with Triton X-100 concentrations ≥ 5 mM.  
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Table 3.2. shows a summary of vesicle categories from various literature sources 23,24,34 
where vesicle size ranges are provided for each category.  The small unilamellar vesicles 
category (SUV) has a range of 15-30 nm and is typical of sonicated vesicle preparations; the 
rarely-used intermediate unilamellar vesicle category ranges from 100-200 nm; the large 
unilamellar vesicle category (LUV)  ranges from 60-500 nm and is used frequently to describe 
extruded liposome preparations. These ranges will be used to compare with the Z-heights 
(approximation of the actual vesicle diameters) obtained by AFM images of the sphingomyelin 
preparation vesicles. 
Atomic force microscopy imagery.  
 AFM measures surface topography of soft solids including phospholipid vesicle bilayers 
at nanomolar resolution. In this technique, the piezoelectric force between the probe tip and the 
surface is quantitated and processed to display an image.36a-d   Figure 3.9 shows a representative 
image of a pure sphingomyelin vesicle preparation (0 mM Triton X-100). In Figure 3.9 (a), the 
1D image shows distinct, round particles which can correspond to small, unilamellar vesicles 
with a mean Z-height of 40 ≤ 12 nm. From this Z-height, the diameter of 40 nm is classified as 
SUV. The histogram for this image shows a medium distribution. For comparison, Figure 3.9 (b) 
shows pure phosphatidylcholine vesicles prepared by aqueous sonication from a dried lipid film 
prepared by Leonenko et al.36b to demonstrate the similarity in vesicle shape for two 
phospholipids. The average diameter in that study was 22 ≤ 2 nm. Vesicles prepared by bath 
sonication typically produce SUVs.34 
The vesicles prepared with 2 mM and 16 mM Triton X-100 revealed anomalous images 
(data not shown). The 2 mM Triton X-100 solubilized vesicles featured two distinct image types 
which may explain the larger standard deviations in the hydrolysis yield data associated with this  
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Figure 3.7.  Graph shows the turbidity measurements of the vesicle to micelle transition of 2 mM 
sphingomyelin in 20 mM piperazine buffer with 0 - 25 mM Triton X-100.  The x-axis is the 
concentration of Triton X-100 and the lower axis shows the molar ratio of lipid: Triton X-100. 
The y-axis is the absorbance at 500 nm. The inset shows similar results with egg yolk lecithin-
dicetylphosphate vesicles taken from Alonso, Villena, Goñi, FEBS Lett., 1981.32c The number of 
trials = 4. 
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Figure 3.8.  Comparison of turbidity for sphingomyelin without and with (0, 50 mole %) 
cholesterol.  Graph shows a comparison of the data shown in Figure 3.7 with the turbidity 
measurements of 2 mM sphingomyelin in 20 mM piperazine buffer and 1 mM cholesterol with 0 
- 100 mM Triton X-100 addition.   
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     Table 3.2.  Summary of vesicle size categories from literature sources.* 
 
 
Liposome Category Diameter size 
range 24 
Diameter size 
range 23 
Diameter size 
range 34 
Small unilamellar vesicles 
(SUV) 
25 nm 22 - 50 nm 15 - 30 nm 
Intermediate-sized 
unilamellar vesicle (IUV) 
100 - 200 nm nd nd 
Large unilamellar vesicle 
(LUV) 
500 nm >60 nm 100 - 200 
   *nd = not determined 
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(a)         (b) 
 
 
Figure 3.9.  Comparison of the AFM images of (a) the pure sphingomyelin from this study 
compared to (b) an image of pure phosphatidylcholine vesicles taken from Z.V. Leonenko, A. 
Cornini, D.T.Cramb, Biochimica et Biophysica Acta (2000).36b Both vesicles were prepared by 
sonication technique from dry film. The Z-height in (a) is approximated as the vesicle diameter. 
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detergent concentration.  The vesicle preparation with 16 mM Triton X-100 amount produced an 
image with a regular clustered molecular array of non-rounded particles.  Close observation of 
the image revealed stacked round particles which may correspond to clustered micelles.  
The Triton X-100 evidently solubilizes the vesicles to produce non-uniform and uniform 
shape distributions.  The images of vesicles prepared with experimental levels of metal and 
buffer are unavailable due to the difficulty in acquiring data on AFM samples with high salt 
content, e.g., cerium(IV) ammonium nitrate. 
Phosphate determination of metal-assisted hydrolysis of pure sphingomyelin at 60 °C. 
A panel of twelve, bi-, tri-, and tetravalent metals metals were each tested for their 
comparative abilities to hydrolyze the phosphate ester bond of pure and Triton X-100 solubilized 
sphingomyelin vesicles to release phosphocholine and/or choline products.  Following this 
hydrolytic cleavage, the released product may undergo secondary cleavage of the remaining 
mono-phosphate bond which occurs at a much lower rate as evidenced by the low hydrolysis 
percentages quantified by the inorganic phosphate assay.  The multiple trials of the metal-
assisted hydrolysis of sphingomyelin preparations at 60 °C were assayed for inorganic phosphate 
concentrations at µmolar levels.  The data for each metal is plotted in Figure 3.10 as a 3D 
histogram and listed in Table 3.3. The histogram shows a comparison of the percent hydrolysis 
by each metal at pH 4.8 and pH 7 (x-axis) as a function of increasing amounts of Triton X-100 
(z-axis), and the percent of phosphate released by metal-assisted hydrolysis (y-axis).  The inset in 
Figure 3.10 shows the results obtained with CeIV since the percentage of phosphate released was 
significantly higher in comparison to the other metals. 
The ranked metals according to their hydrolytic ability are CeIV > > ZrIV > HfIV ≥  PdII > 
all other divalent and trivalent metals.  This ranking correlates with the order of hydrolysis 
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constants in Figure 3.1 especially for CeIV, ZrIV, HfIV, and PdII where the ability to form a metal-
OH nucleophile is best facilitated at low pH values. The pH 4.8 data for ZrIV and HfIV show 
similar trends with 0 mM < 2 mM < 16 mM Triton X-100 which may indicate a Triton X-100-
solubilization dependency. The solubilization of a vesicle which has ~40 % of its headgroups 
inside the vesicle would expose a larger amount in the micelle structure where all polar 
headgroups are exposed.  The phosphate concentration data at pH 4.8 for CeIV show a different 
order of 0 mM < 16 mM < 2 mM.  A 2 mM Triton X-100-solubilized vesicle has more exposed 
headgroups because of reduced Columbic repulsion from Triton X-100 interdigitation than the 
pure sphingomyelin vesicle where the polar headgroups are closer.  For CeIV, ZrIV, and HfIV, 
hydrolysis is considerably enhanced at pH 4.8 compared to pH 7. PdII-assisted  hydrolysis is the 
exception with favorable hydrolysis at pH 7 compared to pH 4.8. Metal speciation may be a 
factor affecting the PdII data. For the CeIV, ZrIV, and HfIV metals, the phosphate yields at pH 7 
shows less Triton X-100 dependency, with the hydrolysis percentages at 2 mM and 16 mM 
having similar yields. The phosphate hydrolysis yields as percentages of the twelve metals are 
listed in Table 3.3.  The highest yields per metal are 70.7 ≤ 7.1% for CeIV (2 mM Triton X-100, 
pH 4.72)  >  11.3 ≤ 2.2% for ZrIV (16 mM Triton X-100, pH 4.87) > 2.21 ≤ 0.25% for HfIV (16 
mM, pH 4.85), and 2.49 ≤ 0.55% for PdII (2 mM, pH 6.98).  Because the highest yields are from 
ZrIV, CeIV, and HfIV, these metal ions would be used in further hydrolysis reactions to be 
analyzed by the Amplex Red assay which quantitates the hydrolysis products of  
phosphocholine and choline. Notwithstanding, the malachite green data showed that CeIV 
produced the highest hydrolysis yields of the 12 tested metals.  For CeIV, hydrolysis yields at pH 
4.8 were statistically higher than hydrolysis yields at pH 7.0, at all Triton X-100 concentrations,  
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Figure 3.10.  The 3D graph with inset ranks the percentage of hydrolysis by various metals as 
measured by the inorganic phosphate release. Solutions were prepared from 2 mM 
sphingomyelin, 10 mM metal, 20 mM piperazine (pH 4.8) or HEPES (pH 7.0), and reacted for 
20 h, at 60 °C. Phosphate levels were determined by the malachite green assay. The inset shows 
the CeIV data with the other metals since the CeIV hydrolysis percentages were much higher. 
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Table 3.3.  Summary of the twelve metals according to the inorganic phosphate quantification 
(µM) for 2 mM sphingomyelin reacted with 10 mM metal at pH 4.8 or pH 7 and 60 °C for 20 h. 
 
Metal 
Avg. 
pH 
Avg. phosphate concentration (µM) ± SD 
(% hydrolysis ± SD) 
n 0 mM 
Triton X-100 
2 mM 
Triton X-100 
16 mM 
Triton X-100 
CeIV 4.72 444 ≤ 100 
(22.2 ≤ 5.4) 
1413 ≤140 
(70.7 ≤ 7.1) 
861 ≤ 130 
(43.0 ≤ 6.8) 
13-15 
7.05 102 ≤ 39 
(5.08 ≤ 1.9) 
332 ≤ 91 
(16.6 ≤ 4.6) 
380 ≤ 70 
(19.0 ≤ 3.5) 
11-12 
ZrIV 4.87 4.36 ≤ 4.4 
(0.22 ≤ 0.20) 
112 ≤ 44 
(5.62 ≤ 2.2) 
226 ≤ 43.1 
(11.3 ≤ 2.2) 
18-19 
7.04 3.68 ≤ 4.2 
(0.18 ≤ 0.2) 
60.5 ≤ 28 
(3.03≤ 1.4) 
61.8 ≤ 25 
(3.09 ≤ 1.2) 
15-18 
HfIV 4.85 0.21 ≤ 1.3 
(0.01 ≤ 0.05) 
16.9 ≤ 3.7 
(0.85 ≤ 0.2) 
44.1 ≤ 5.0 
(2.21≤ 0.3) 
6 
7.09 0.13 ≤ 0.8 
(0.01 ≤ 0.05) 
2.74 ≤ 2.9 
(0.14≤ 0.2) 
11.6 ≤ 3.8 
(0.58 ≤ 0.2) 
5-7 
PdII 4.91 -1.05 ≤ 2.6 
(-0.05 ≤ 0.1) 
-3.16 ≤ 5.0 
(-0.16 ≤ 0.2) 
6.32 ≤ 3.7 
(0.32 ≤ 0.2) 
2 
6.98 12.0 ≤ 1.2 
(0.60 ≤ 0.05) 
50.0 ≤ 11 
(2.49 ≤ 0.6) 
27.2 ≤ 4.7 
(1.36 ≤ 0.2) 
2 
CuII 4.85 3.41 ≤ 1.2 
(0.17 ≤ 0.05) 
0.24 ≤ 2.7 
(0.01 ≤ 0.1) 
-0.24 ≤ 0.7 
(-0.01 ≤ 0.05) 
2 
7.09 7.16 ≤ 9.1 
(0.36≤0.5) 
-0.25 ≤ 5.7 
(-0.01≤ 0.3) 
3.46 ≤ 2.2 
(0.17 ≤ 0.1) 
2 
NiII 4.87 3.86 ≤ 4.6 
(0.19≤0.2) 
-0.48 ≤ 2.6 
(-0.02 ≤ 0.1) 
1.69 ≤ 1.0 
(0.08 ≤ 0.05) 
2 
7.05 2.65 ≤ 6.0 
(0.13≤ 0.3) 
2.65 ≤ 1.0 
(0.13 ≤ 0.05) 
-0.96 ≤ 2.7 
(-0.05 ≤ 0.13) 
2 
ZnII 4.90 3.40 ≤ 3.4 
(0.17≤ 0.2) 
2.20 ≤ 5.2 
(0.11 ≤ 0.3) 
1.40 ≤ 2.2 
(0.07 ≤ 0.10) 
2 
7.13 -0.20 ≤ 0.8 
(-0.01≤ 0.05) 
1.22 ≤ 4.3 
(0.06 ≤ 0.2) 
-1.22 ≤ 0.82 
(-0.06 ≤ 0.04) 
2 
CoII 4.86 4.42 ≤ 1.5 
(0.22 ≤ 0.1) 
-0.42 ≤ 3.6 
(-0.02 ≤ 0.2) 
-1.89 ≤ 0.84 
(-0.09 ≤ 0.04) 
2 
7.10 -2.71 ≤ 0.6 
(-0.14 ≤ 0.05) 
0.00 ≤ 1.5 
(0.00 ≤ 0.1) 
-0.21 ≤ 0.21 
(-0.01 ≤ 0.01) 
2 
EuIII 4.90 -1.56 ≤ 1.8 
(-0.08 ≤ 0.1) 
0.44 ≤ 4.7 
(0.02 ≤ 0.2) 
1.33 ≤ 0.9 
(0.07 ≤ 0.04) 
2 
7.18 -3.83 ≤ 0.9 
(-0.19 ≤ 0.05) 
-4.04 ≤1.3 
(-0.20 ≤ 0.05) 
0.85 ≤ 1.9 
(0.04 ≤ 0.1) 
2 
n = number of trials for both pH values 
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Continued Table 3.3.:  Summary of the twelve metals according to the inorganic phosphate 
quantification (µM) for 2 mM sphingomyelin reacted with 10 mM metal at pH 4.8 or pH 7 and 
60 °C for 20 h. 
 
Metal Avg. 
pH 
Avg. phosphate concentration (µM) ± SD 
(% hydrolysis ± SD) 
n 
0 mM 
Triton X-100 
2 mM 
Triton X-100 
16 mM 
Triton X-100 
LaIII 
4.91 -7.16 ≤ 0.0 
(-0.36 ≤ 0.0) 
-1.26 ≤ 0.8 
(-0.06 ≤ 0.05) 
-1.05 ≤ 1.5 
(-0.05 ≤ 0.07) 
2 
7.10 -4.01 ≤1.5 
(-0.20 ≤ 0.07) 
-1.69 ≤ 1.1 
(-0.08 ≤ 0.05) 
0.42 ≤ 1.3 
(0.02 ≤ 0.06) 
2 
YIII 
4.93 -1.01 ≤ 0.0 
(-0.05 ≤ 0.0) 
-0.20 ≤ 1.6 
(-0.01 ≤ 0.08) 
1.01 ≤ 0.0 
(0.05 ≤ 0.0) 
2 
7.20 -6.21 ≤ 0.8 
(-0.31 ≤ 0.04) 
-2.00 ≤ 1.8 
(-0.10 ≤ 0.1) 
0.20 ≤ 2.2 
(0.01 ≤ 0.1) 
2 
YbIII 
4.86 -3.96 ≤ 1.7 
(-0.20 ≤ 0.08) 
-0.42 ≤ 0.2 
(-0.02 ≤ 0.01) 
-0.42 ≤ 0.4 
(-0.02 ≤ 0.02) 
2 
7.14 -2.13 ≤ 2.3 
(-0.11 ≤ 0.1) 
-2.13 ≤ 1.7 
(-0.11≤ 0.1) 
3.19 ≤ 0.85 
(0.16 ≤ 0.04) 
2 
n = number of trials for both pH values 
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Figure 3.11.  The histogram of zirconocene dichloride and ZrCl4-assisted hydrolysis of 
sphingomyelin at pH 4.8 and pH 7 with the hydrolysis yields calculated from phosphate 
concentrations. Samples were prepared with 2 mM sphingomyelin, 10 mM metal, and 20 mM 
buffer at pH 4.8 or 7 and reacted at 60 °C for 20 h.  The zirconocene dichloride experiments 
were conducted over 5 trials. The ZrCl4 experiments were conducted over 15-19 trials.   
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Figure 3.12.  Graph shows the comparison of sphingomyelin hydrolysis yields produced by three 
metals as measured by total phosphocholine plus choline and total choline.  Hydrolysis 
percentages are for 2 mM sphingomyelin, 10 mM metal, 20 mM piperazine buffer (pH 4.8) or 
HEPES buffer (pH 7.0) and 0, 2, or 16 mM Triton X-100 treated at 60 °C for 20 h. For ZrIV and 
CeIV, n = 7, for HfIV, n = 3, where n = number of trials. 
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Table 3.4.  Summary of the percentage hydrolysis from total phosphocholine plus choline 
concentrations and the choline-only concentrations for ZrIV, HfIV, and CeIV metal-assisted 
hydrolysis for 2 mM sphingomyelin reacted with 10 mM metal at pH 4.8 or pH 7 and 60 °C for 
20 h. The results are shown in Figure 3.12. 
 
 
Metal 
 
pH 
Percentage Hydrolysis for Total Phosphocholine plus Choline 
Concentrations, Avg ± SD 
(Percentage Hydrolysis for Choline-only Concentrations,  Avg ± SD)  
n 0 mM 
Triton X-100 
2 mM 
Triton X-100 
16 mM 
Triton X-100 
ZrIV 4.8 2.33 ≤ 0.27 
(1.17 ≤ 0.33) 
19.3 ≤ 2.8 
(13.6 ≤ 0.69) 
73.0 ≤ 7.6 
(51.1 ≤ 2.9) 
7 
7 2.50 ≤ 0.26 
(1.58 ≤ 0.27) 
17.4 ≤ 2.3 
(16.6 ≤ 1.3) 
61.9 ≤ 3.3 
(47.6 ≤ 5.4) 
7 
HfIV 4.8 1.38 ≤ 0.04 
(0.74 ≤ 0.05) 
9.40 ≤ 0.71 
(7.75 ≤ 0.28) 
33.2 ≤ 4.8 
(26.2 ≤ 0.87) 
3 
7 1.13 ≤ 0.18 
(1.20 ≤ 0.57) 
4.53 ≤ 0.71 
(3.60 ≤ 0.14) 
23.3 ≤ 1.3 
(20.6 ≤ 2.5) 
3 
CeIV 4.8 56.8 ≤ 3.1 
(54.4 ≤ 3.8) 
81.2 ≤ 5.8 
(81.3 ≤ 6.8) 
88.7 ≤ 6.4 
(83.8 ≤ 4.1) 
7 
7 9.43 ≤ 1.6 
(7.58 ≤ 1.3) 
30.0 ≤ 2.2 
(24.6 ≤ 5.0) 
47.6 ≤ 7.3 
(44.8 ≤ 5.4) 
7 
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with the highest cleavage levels being produced at pH 4.8 in the presence of 2 mM Triton X-100, 
a concentration of surfactant which would be expected to produce mixed sphingomyelin vesicles. 
The histogram in Figure 3.11 compares the percent hydrolysis as determined by 
phosphate assay results for zirconocene dichloride and ZrCl4 in order to compare two ZrIV  
complexes.  Zirconocene dichloride is a non-toxic metallocene which has been used safely in 
clinical trials.37  The data at pH 4.8 for both metals show a similar Triton X-100-solubilization 
dependencies as the percentage hydrolysis for 0 mM < 2 mM < 16 mM Triton X-100 amounts 
and are statistically similar.  Both data sets at pH 7 shows that 0 mM < 2 mM ≈ 16 mM, and the 
zirconocene dichloride yields are slightly higher than ZrCl4. For ZrCl4 and zirconocene 
dichloride, reactivity is greater at lysosomal pH (4.8) than at cytosolic (7.0) pH only at 16 mM 
Triton X-100, with ZrCl4 showing the highest differential cleavage at pH 4.8.    
Quantification of phosphocholine and choline in metal-assisted hydrolysis reactions at 60 
°C using an Amplex Red method. 
The hydrolysis of the phosphate ester bonds of sphingomyelin generates phosphocholine 
and choline.  The phosphocholine and choline products produced in metal-assisted hydrolysis 
reactions were quantified by Amplex Red assay.  A novel adaptation of the assay’s enzyme 
mix, whereby only the choline product is measureable, allowed differential quantification of the 
total phosphocholine plus choline products vs. the choline product (and thus phosphocholine 
concentrations indirectly by difference).  Figure 3.12 shows the compilation of results of 
multiple sphingomyelin hydrolysis reaction trials at 60 °C for the three metals, ZrIV, HfIV, and 
CeIV since these tetravalent metals produced the highest hydrolysis yields in the malachite green 
phosphate detection assay (Figure 3.10).  The Amplex Red data show that the order of metal 
reactivity for the hydrolysis of 2 mM sphingomyelin in the presence of 10 mM metal and 20 mM 
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buffer at 60 °C for 20 h is CeIV > ZrIV > HfIV (Figure 3.12). This trend correlates with the pKa 
order of metals and their ability to form a hydroxide-bound metal complex which serves as a 
nucleophile in the phosphate ester hydrolysis reaction (Figure 3.1). 
The pure sphingomyelin vesicles were solubilized by increasing amounts (0, 2, and 16 
mM) of Triton X-100.  For all three metals, the increased Triton X-100 levels were correlated to 
higher yields presumably due to the bilayer to monolayer transition with increased phosphate 
ester bond exposure on the exovesicular layer of the liposome. Also, the increased Triton X-100 
interdigitation within the vesicle bilayer reduces columbic repulsion so that the metal-OH 
nucleophile may react in a more facile fashion. 
The experiments at each Triton X-100 were performed at two different pH values which 
simulate the lysosomal pH 4.8 and the cytosolic pH 7.0 at 60 °C.  The maximum hydrolysis 
yields per metal and per Triton X-100 amount as measured by the total phosphocholine and 
choline assay are 73.0 ≤ 7.55% for ZrIV (16 mM Triton X-100 , pH 4.8), 33.2 ≤ 4.77% for HfIV 
(16 mM Triton X-100, pH 4.8), and 88.7 ≤ 6.40% for CeIV (16 mM Triton X-100, pH 4.8).  
The data in Figure 3.12 for ZrIV and HfIV show that the hydrolysis yields at 60 °C are not 
significantly enhanced at lysosomal pH since the ratios of yields pH 4.8: pH 7.0 for ZrIV are 0.93 
(0 mM), 1.11 (2 mM), 1.18 (16 mM); and for HfIV are 1.21 (0 mM), 2.07 (2 mM), 1.42 (16 mM). 
A value  <  1 signifies no pH enhancement of hydrolysis in lysosome compared to cytosol, while 
a value > 1 shows reactivity that is has greater yields in the lysosome. In contrast, CeIV shows a 
significant enhancement in yields at lysosomal pH compared to cytosolic pH at 60 °C, with ratio 
of yields (pH 4.8: pH 7) of 6.02 (0 mM), 2.70 (2 mM), and 1.86 (16 mM).   
The novel, modified choline-only assay is plotted alongside the total phosphocholine and 
choline results.  Choline differentiation from the phosphocholine yields is important factor in the 
90 
 
determination of the regioselectivity of a metal-hydrolytic agent and its ability to mimic the acid 
sphingomyelinase enzyme although this neglects the dephosphorylation of the phosphocholine 
product which could occur as a secondary metal-assisted hydrolysis reaction. The choline 
product produced is approximately the same at pH 4.8 and pH 7 for ZrIV and HfIV while CeIV 
shows much more choline produced much more at pH 4.8 than at pH 7. For ZrIV, HfIV, and CeIV 
metals, the choline at pH 4.8 is less than the total phosphocholine plus choline amounts and 
ranges from 50-70 % for ZrIV, 54-82% for HfIV, and 95-100 % for CeIV of the total 
phosphocholine plus choline yields. The choline at pH 7 is also less than the total 
phosphocholine plus choline amounts and ranges from 63-95% for ZrIV, 79-106% for HfIV, and 
80-94% for CeIV of the total phosphocholine plus choline yields.  The predominance of choline 
product may originate from two pathways: 1) the metal preferentially hydrolyzes the choline side 
of the phosphate ester bond of sphingomyelin due to steric effects, or 2) phosphocholine 
hydrolysis product is hydrolyzed to choline and inorganic phosphate due to a labile phosphate, 
although the inorganic phosphate levels determined in the malachite green assay do not account 
for the differences between phosphocholine and choline.  For CeIV, the choline yields are 
approximately the same yields as the total which indicates either very little phosphocholine 
product or an advanced degree of dephosphorylation of the phosphocholine product. 
Cholesterol effects on sphingomyelin vesicles at 37 °C and at 60 °C. 
Cholesterol plays a key role in phospholipid membranes because it modulates the 
structure, dynamics, and function of the bilayer.  Cholesterol increases the cross-sectional 
packing of the phospholipid bilayer with denser packing.   Since cholesterol induces tighter 
packing within the bilayer and thus  higher columbic repulsion within the polar headgroup region 
of sphingomyelin vesicles, the predicted result is less metal-polar headgroup interaction and, 
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consequently,  reduced hydrolysis.23,24,28,32j-k  Niemann-Pick cells show elevated cholesterol in 
the liver and spleen cells that cause a characteristic foamy appearance. Lipid compositional 
analysis of a Niemann-Pick Type A patient’s cerebral cortex showed 27.6 µmol/g wet wt. 
cholesterol with 31.9 µmol/g sphingomyelin compared to the control patient’s cerebral cortex 
which had 24 µmol/g wet wt. cholesterol and 4.1  µmol/g wet wt.  sphingomyelin.  The cerebral 
white matter show 37 µmol/g wet wt. cholesterol and 28.3 µmol/g wet wt. sphingomyelin 
compared to the control patient’s cerebral white matter which had 118.5 µmol/g wet wt. 
cholesterol and 112.1 µmol/g wet wt. sphingomyelin.38,33b Given these elevated cholesterol 
levels, sphingomyelin vesicles with 50 mole % cholesterol were hydrolyzed in the presence of 10 
mM metal and 20 mM buffer to represent a balance between normal physiological cholesterol 
levels and high levels observed in Niemann-Pick Type A patients.  
Figure 3.13 shows several trends for ZrIV including a large reduction in hydrolytic yields 
when cholesterol is present, the similar yields for both pH 4.8 and 7.0 as observed in the use of 
pure sphingomyelin without cholesterol (Figure 3.12), and the total phosphocholine plus choline 
amounts are slightly greater than the choline. In Figure 3.13, vesicles with sphingomyelin and 50 
mol % cholesterol were hydrolyzed with ZrIV at both 60 °C and 37 °C for 20 h.  The overall 
yields have decreased by half compared to the reactions without cholesterol.  In addition, yield 
percentages as a function of Triton X-100 concentration follow the general trends of the non-
cholesterol data for both pH 4.8 and 7 with 0 mM < 2 mM < < 16 mM. The Figure 3.13 (a) 
shows the maximum ZrIV-assisted yields at 60 °C: 31.4 ≤ 1.3% (16 mM Triton X-100, pH 4.8) 
and  28.6 ≤ 1.1% (16 mM Triton X-100, pH 7) compared to 73.0  ≤ 7.6% (16 mM) at pH 4.8 and 
61.9 ≤ 3.3% (16 mM) at pH 7 without cholesterol. (Figure 3.12 and Table 3.4)  For the 60 °C 
data, cholesterol reduces the hydrolytic yields by 2-4 times. The hydrolysis yields at 37 °C are 
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much lower than the 60 °C. The overall yields at 37 °C in Figure 3.13 (b) show a maximum at 
1.13 ≤ 0.49% (16 mM Triton X-100, pH 4.8) and  at 1.02 ≤ 0.09%  (16 mM Triton X-100, pH 
7).  The trends for the hydrolysis yield ratios at lysosomal pH 4.8 to cytosolic pH 7.0 are similar 
to the pure sphingomyelin vesicles without cholesterol at 60 °C where no pH advantage at pH 
4.8 or 7 occurs in hydrolysis (Figure 3.12 and Figure 3.13). 
The trends in hydrolytic yields as determined by phosphate concentrations are similar to 
the total phosphocholine plus choline yields except at 16 mM, pH 7 which shows a slightly lower 
phosphate yield than expected (Figure 3.13).   
 The cholesterol sphingomyelin reactions were then repeated for CeIV. Figure 3.14 (a-d) 
plots the hydrolysis yields for CeIV-assisted sphingomyelin vesicles that contain 50 mol % 
cholesterol. Figure 3.14 (a-d) shows several new trends: the addition of cholesterol reduces the 
hydrolysis yields to a lesser degree than ZrIV (Figure 3.13), yields at pH 4.8 are reduced to a 
greater extent than at 7.0, and the maximum 60 ° C hydrolysis yields are highest at 2 mM Triton 
X-100. Unlike the ZrIV data (37 °C and 60 °C; Figure 3.13), the maximum yields at 60 °C shown 
in Figure 3.14 (a) occur at 2 mM Triton X-100 for both pH 4.8 and 7 with 69.4 ≤ 6.7 % (2 mM, 
pH 4.8)  and 37.4 ≤ 9.2% (2 mM, pH 7) compared to the non-cholesterol hydrolysis percentages 
of 81.2 ≤ 5.8% (2 mM, pH 4.8) and 30.0 ≤ 2.2% (2 mM, pH 7).  The overall Triton X-100 
rankings at 60 °C show that pH 4.8 and pH 7.0 trends are very different: 0 mM < 16 mM < 2 
mM (pH 4.8) and 0 mM ~ 2 mM ~ 16 mM (pH 7.0). The pH 7 hydrolysis yields are elevated 
compared to Figure 3.12 where there was a dramatic difference between pH 4.8 and pH 7 in the 
non-cholesterol data. As seen in Table 3.5 for CeIV metal, the 0 and 2 mM Triton X-100 
hydrolysis yields at pH 7 show reversed trends with the 50 mol % cholesterol reactions 
producing higher yields with cholesterol than without.  Overall, the majority of the 60 °C data 
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shows between 1-2 times lower hydrolytic yields with cholesterol except for the two pH 7 
reactions which are 1 and 3.5 times greater.  The 37 °C hydrolysis yields in Figure 3.14 (b) show 
maxima at 16 mM Triton X-100 for both pH 4.8 and 7.0 with 21.3 ≤ 1.4% (16 mM Triton X-
100, pH 4.8) and 11.3  ≤ 0.51% (16 mM Triton X-100, pH 7).  The phosphate assay shows 
similar trends in Figure 3.14 (c-d) with 60 °C hydrolysis reactions producing maximum yields at 
2 mM Triton X-100, and 37 °C hydrolysis reactions producing maximum yields at 16 mM Triton 
X-100.  The pH 4.8 yields show a slight increase over the pH 7.0 yields at both 37 °C and 60 °C.  
The comparison of 60 °C hydrolysis yields for sphingomyelin vesicles with 0 % (Figure 
3.12) and 50 mol % cholesterol (Figures 3.13 and 3.14 and Table 3.5) shows less attenuation in 
hydrolytic yields for CeIV than for ZrIV. For the majority of the CeIV data, the presence of the 
cholesterol reduces yields by 1.17 - 1.82 times excluding the above mentioned pH 7.0 reactions. 
Time course studies of the metal-assisted hydrolysis reactions of sphingomyelin. 
 A major emphasis of this study is to investigate differential levels of hydrolysis at pH 4.8 
versus pH 7 to assess the physiological differences that may occur between the lysosomal and 
the cytosolic pH for a potential metal-based therapeutic drug. Figure 3.15 (a-b) plots the ratio of 
ZrIV and CeIV hydrolysis yields (pH 4.8/pH 7.0) from the total phosphocholine plus choline assay 
results at pH 4.8 and pH 7. A ratio greater than one indicates that hydrolysis is favored at pH 4.8 
over pH 7 which may predict higher reactivity in the lysosome compared to the cytosol in a 
cellular environment. The majority of the ZrIV plots in Figure 3.15 show that at 37 °C and 60 °C, 
the maximum  ratio, and thus enzyme mimicry, occurs at 4 h and decreases slightly to a constant 
level.  
For ZrIV at 0 mM Triton X-100 and 37 °C, this pH 4.8 advantage is most dramatic since 
the ratio at t = 4 h approaches five (Figure 3.15).  The results illustrate that ZrIV hydrolysis of  
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Figure 3.13.  Yields produced by ZrIV hydrolysis of sphingomyelin with 50 mole % cholesterol 
at 60 °C and 37 °C.  The percentage hydrolysis of  total phosphocholine plus choline or the 
modified choline-only assays are shown in (a-b) while the percentage hydrolysis as calculated 
from free inorganic phosphate are shown in (c-d). Samples prepared with 2 mM sphingomyelin, 
10 mM ZrCl4, 20 mM piperazine (pH 4.8) or HEPES (pH 7.0), and 1 mM cholesterol were 
reacted at 60 °C and 37 °C for 20 h. The number of trials = 3.  
(a) (b) 
(c) (d) 
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Figure 3.14.  Yields produced by CeIV hydrolysis of sphingomyelin with 50 mole % cholesterol 
at 60 °C and 37 °C.  The percentage hydrolysis of total phosphocholine plus choline or the 
modified choline-only assays are shown in (a-b) while the percentage hydrolysis as calculated 
from free inorganic phosphate are shown in (c-d). Samples prepared with 2 mM sphingomyelin, 
10 mM CeIV ammonium nitrate, 20 mM piperazine (pH 4.8) or HEPES (pH 7.0), and 1 mM 
cholesterol were reacted at 60 °C and 37 °C for 20 h. The number of trials = 3.  
 
 
 
(a) (b) 
(c) (d) 
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Table 3.5.  Percent hydrolysis yields of total phosphocholine plus choline for sphingomyelin 
reacted at 60 °C with 0 and 50 mol % cholesterol for ZrIV and CeIV.  
 
   
Hydrolysis percentage 
average ± SD % 
Metal Triton X-100 
(mM) 
pH 0 mol % cholesterol 50 mol % cholesterol 
ZrIV 0 4.8 2.33 ≤ 0.27 0.57 ≤ 0.01 
  7 2.50 ≤ 0.26 1.2 ≤ 0.03 
 2 4.8 19.3 ≤ 2.8 8.8 ≤ 0.2 
  7 17.4 ≤ 2.3 5.1 ≤ 0.7 
 16 4.8 73.0 ≤ 7.6 31.4 ≤1.3 
  7 61.9 ≤ 3.3 28.6 ≤ 1.1 
CeIV 0 4.8 56.8 ≤ 3.1 39.9 ≤ 7.0 
  7 9.43 ≤ 1.6 33.8 ≤ 9.4 
 2 4.8 81.2 ≤ 5.8 69.4 ≤ 6.7 
  7 30.0 ≤ 2.2 37.4 ≤ 9.2 
 16 4.8 88.7 ≤ 6.4 59.7 ≤ 3.6 
  7 47.6 ≤ 7.3 26.1 ≤ 6.6 
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Figure 3.15.  Time course experiments showing ratios of pH 4.8 total phosphocholine plus 
choline yields to pH 7.0 total phosphocholine plus choline yields at 37 °C and 60 °C as a 
function of Triton X-100 concentration. Samples were prepared with 2 mM sphingomyelin, 10 
mM metal ZrCl4 (shown in (a)) or Ce(NH4)2(NO3)6 (shown in (b)), 20 mM piperazine or HEPES 
were reacted at 37 °C and 60 °C for 20 h. Ratios were taken from the total phosphocholine and 
choline results of the Amplex Red-based assay.The number of trials = 4. CeIV and ZrIV yields 
are plotted in Figures 3.17 and 3.20. 
 
 
 
 
(a) (b) 
98 
 
 
 
Figure 3.16.  Time course experiments showing ratios of pH 4.8 choline yields to pH 7.0 choline 
yields at 37 °C and 60 °C as a function of Triton X-100 concentration. Samples prepared with 2 
mM sphingomyelin, 10 mM metal (ZrCl4 shown in (a)) or (Ce(NH4)2(NO3)6 shown in (b)), 20 
mM piperazine or HEPES were reacted at 37 °C and 60 °C for 20 h. Ratios were taken from the 
choline results of the Amplex Red-based assay. The plot in (a) only shows the 60 °C data since 
the 37 °C data is below detection. The number of trials = 4. CeIV and ZrIV yields are in Figures 
3.18 and 3.21. 
 
 
 
 
 
 
 
(a) (b) 
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pure sphingomyelin vesicles is significantly enhanced at lysosomal pH at physiological 
termperature. The ratios at 2 and 16 mM Triton X-100 for 37 °C are also greater than one.  At the 
higher temperature of 60 °C, the ratios at 0, 2, and 16 mM Triton X-100 for ZrIV hydrolysis are 
approximately one which indicates no pH preference. 
While the overall yields of CeIV are higher than ZrIV for 0, 2, and 16 mM Triton X-100, 
the pH advantage at lysosomal pH 4.8 is not significant.  At 60 °C, the pH ratio of yields shows a 
slight advantage especially at 4 h, but levels off to a ratio of one at longer reaction times.  The 37 
°C data show that the pH ratio of yields at 0, 2 and 16 mM are approximately one. 
Figure 3.16 shows a corollary graph to the previous Figure 3.15 where the pH ratio of the 
modified choline-only assay yields are plotted.  Similar trends in the ZrIV data are observed 
compared to the previous figure except that the 37 °C, 0 mM Triton X-100 data is negligible.  
For the CeIV plots, only the 60 °C shows a pH 4.8 advantage with ratios slightly greater than  1, 
while the 37 °C shows no pH advantage since the ratios are approximately equal to unity. 
Percentage hydrolysis by total phosphocholine plus choline, modified choline-only, and 
phosphate assays at 37 °C and 60 °C. 
 CeIV-assisted and ZrIV-assisted hydrolysis. The hydrolysis yields used to produce ratios 
shown in Figures 3.15 and 3.16 are shown in Figures 3.17, 3.18, 3.19, 3.20, 3.21, and 3.22. The 
percentage of hydrolysis at 37 °C and 60 °C as calculated by the total phosphocholine plus 
choline assay is on the y- axis of each figure (Figure 3.17 and 3.20) or the modified choline-only 
assay is on the y-axis of each figure (Figure 3.18 and 3.21). Figures 3.17 and 3.18 show the 
progression of hydrolysis reactions of 2 mM of pure sphingomyelin vesicles as well as 
sphingomyelin solubilized by 0, 2, or 16 mM amounts of Triton X-100 detergent in the presence 
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of 10 mM cerium(IV) ammonium nitrate and 20 mM piperazine (pH 4.8) or HEPES (pH 7). The 
pH differences between the hydrolysis percentages at 37 °C and 60 °C at 20 h are fully discussed 
in a later section and presented in Table 3.11.  At 37 °C, the pH 4.8 and 7 data almost overlapped 
with differences < 10 % for the total phosphocholine plus choline assay (Figure 3.17). The 60 °C 
data show that at pH 4.8, the hydrolysis is higher than at pH 7 by ~25 - 30% at all timpoints. 
Thus, the extreme pH-dependence (pH 4.8 > pH 7.0) in hydrolytic yields demonstrated at 60 ±C 
disappears at 37 ±C.   The early timepoints of 4 h and 8 h show slower kinetics in the presence of 
0 mM Triton X-100 (pure vesicle) compared to the 16 mM (micelles). Figure 3.19 shows the 
phosphate release during the reaction. 
Figure 3.20 and 3.21 show the progression of the hydrolysis reactions of 2 mM pure 
sphingomyelin vesicles at 0, 2, and 16 mM amounts of Triton X-100 detergent in the presence of 
10 mM ZrCl4 and 20 mM piperazine (pH 4.8) or HEPES (pH 7).  At 37 °C (Figure 3.20 (a) and 
Figure 3.21 (b)), the percentage of hydrolysis at 0 and 2 mM is barely detectable while 16 mM 
Triton X-100 levels show pH 4.8 > pH 7.  At 60 °C (Figure 3.20 (b) and 3.21 (b), the pH 4.8 and 
7 slopes almost overlap.  The phosphate amounts in Figure 3.22 are approximately 10 % of the 
total phosphocholine plus choline results. 
This data demonstrate that the regioselective hydrolysis by metals at the phosphate ester 
bond to release phosphocholine is not favored in this cleavage reaction since the high choline 
percentages indicate that the metals hydrolyze the polar side of the molecule to release choline. 
The choline side of the phosphate ester bond also represents less steric hindrance. The acid 
sphingomyelinase enzyme solely releases phosphocholine in the lysosomes. However, the metal-
assisted hydrolysis of the primary product of phosphocholine to release inorganic phosphate and 
a secondary product of choline is a very likely possibility due to the phosphate and choline levels 
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detected in the hydrolysis of the phosphocholine positive control. This being said, the MALDI 
mass spectra in Figure 3.23 show the increase of choline in a metal-assisted hydrolysis of 
phosphocholine. 
Estimated half-lives of ZrIV- and CeIV-assisted reactions at 60 °C and 37 °C.   Table 
3.10 shows the estimated half lives (t½) in units of hours for the reactions shown in Figures 3.17 - 
3.22 according to the total phosphocholine plus choline assay and the choline assay results. The 
assays contained the four datapoints from t = 0, 4, 8, and 20 h from which the data was 
approximated. For each of the CeIV or ZrIV reactions, the half-lives were estimated from multiple 
time course experiments with linear plots of the natural log of the remaining unreacted 
sphingomyelin (ln P0 – Ptime) as a function of time according to a slope equation criteria that 
correlation coefficient of R be ≥ 0.98. Plots which produced correlation coefficients less than 
0.98 or whose reaction was too slow and produced extremely long half-lives were listed in the 
table as “nd” for “not determined”. According to the linear fit slope equations from each 
experiment’s plots, the (-) slope = k and t1/2 = 0.693/k values were calculated to obtain the half-
life. 
The half-life is the inverval required for the quantity to decay to half of its initial value. 
Since the total experimental times were 20 h, only the 60 °C data for CeIV (0, 2, and 16 mM 
Triton X-100) and ZrIV data (16 mM only) have half-lives less than the 20 h time cut-off. Table 
3.10. shows that at 60 °C data, CeIV  had the shortest half-lives with a range of 5 h ≤ 0.5 (total 
phosphocholine plus choline assay, 2 mM Triton X-100, pH 4.86) to 19 h ≤ 1 (total 
phosphocholine plus choline assay, 0 mM Triton X-100, pH 6.95). Also at 60 °C, the half-lives 
for ZrIV ranged from 7 h ≤ 0.5 (total phosphocholine plus choline assay, 16 mM, pH 7.07) to 300 
h ≤ 1 (total phosphocholine plus choline assay, 0 mM Triton X-100, pH 4.84). For CeIV, the 
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shortest half-life of 5 h (total phosphocholine plus choline assay, 2 mM Triton X-100, pH 4.86, 
60 °C) represents four half-lives in a total 20 h reaction time where 93.8 % of the sphingomyelin 
is reacted. For ZrIV, the shortest half-life of 7 h (total phosphocholine plus choline assay, 16 mM 
Triton X-100, pH 7.07, 60 °C) represents approximately three half-lives in a 20 h reaction time 
where 87.5% of the sphingomyelin is reacted. At 37 °C, the CeIV had the shortest half-lives of 20 
h ≤ 0.5 (total phosphocholine plus choline assay, 16 mM Triton X-100, pH 7.06) to 80 h ≤ 1 
(total phosphocholine plus choline assay, 0 mM Triton X-100, pH 4.78 and pH 7.02). The 
estimated half-lives for ZrIV at 37 °C range from 100 h ≤ 1 (total phosphocholine plus choline 
assay, 16 mM Triton X-100, pH 4.90) to 7000 h ≤ 2 (0 mM Triton X-100, pH 7.04). The plots 
from the choline assay produced half-lives which lagged the half-lives calculated from the total 
phosphocholine plus choline assay. 
MALDI spectra for phosphocholine.  
Figure 3.23 shows the MALDI mass spectra of the ZrIV-assisted hydrolysis of 
phosphocholine used as a positive control. A total of 2 mM phosphocholine was reacted with 10 
mM ZrCl4 at 0, 5, and 23 h timepoints at 60 °C, 20 mM Tris buffer, pH 4.8. The experiment was 
conducted to validate the dephosphorylation of the phosphocholine molecule to produce a 
choline product. Only the mass range of 90 - 140 Da is shown in order to reduce the complexity 
of the spectra with other unrelated mass peaks such as solvent cluster peaks. The Tris buffer 
mass peak at m/z 122 is present in a constant 20 mM concentration and serves as a reaction 
surrogate been subjected to the experimental conditions and treatments as the phosphocholine 
analyte.  At 0 h, a small choline product appears at < 10%. Its presence may be attributed to 
either pre-reaction degradation of phosphocholine or a choline impurity.  The choline mass peak 
intensifies from 35% (5 h) to 100% (23 h) of the spectra as a product of the phosphocholine 
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hydrolysis. While the MALDI analysis variability in peak heights prevents strict quantification, 
an approximation of the reaction progress of the metal-assisted dephosphorylation can be made. 
 pH drift of the metal-assisted experiments. 
The piperazine and HEPES buffers used in the experiments were chosen because their 
pKa values indicated potential buffering in the pH regions that simulate lysosomal (pH 4.8) and 
cytosolic (pH 7.0). The pKa of piperazine is 5.33 with a buffer range of 5 - 6. The pKa of HEPES 
is 7.5 with a buffer region of 6.8 to 8.2. Additionally, the piperazine buffer does not contain a 
carboxylate group, a reactive functional group to the oxophilic metals, like the majority of the 
buffers in the pH 3 - 5 range.  Table 3.11 shows the average pH and the DpH values for all of the 
experiments combined in order to see the extent of the pH drifts within the 20 h experiments  
conducted in this study.  The pH drift value was calculated from the difference in pH at t = 0 h 
and t = 20 h (0 h – 20 h) which is equal to the DpH values. The lysosomal pH 4.8 data in the 
table shows that ZrIV- or HfIV-assisted experiments showed good pH control with pH drift from -
0.02 to 0.03  from the original 0 h pH setpoint at 60 °C (ZrIV and HfIV) and 0.01 to 0.1 at 37 °C 
(ZrIV only). The zirconocene and non-metal controls showed similar pH drifts. The CeIV reaction 
pH showed higher pH drifts in the range of 0.42 to 0.48 at 60 °C and 0.17 to 0.37 at 37 °C. The 
phosphocholine hydrolysis experiments showed the highest pH drift, 0.53 at 60 °C. Since the pH 
drift in the piperazine-buffered experiments is approximately correlated with hydrolysis yields, 
i.e., the greater the hydrolysis, the greater the pH drift, the proton flux generated during the 
hydrolysis was greater than the buffering capacity. 
The buffering at pH 7 showed less drift in pH during the reactions. For the cytosolic pH 7 
experiments buffered by HEPES, the pH drift of ZrIV or HfIV experiments ranged from -0.03 to 
0.02 at 60 °C (ZrIV and HfIV) and -0.05 to 0.03 at 37 °C (ZrIV only).   
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              (a)            (b) 
 
 
Figure 3.17.  The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM CeIV 
ammonium nitrate at pH 4.8 or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as 
calculated by total phosphocholine plus choline concentrations. The graphs in column (a) are 
results at 37 °C and the graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is 
the percentage of hydrolysis calculated from the Amplex Red assay results of total 
phosphocholine and choline. Corresponding yield ratios are in Figure 3.15 (b). 
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   (a)                            (b) 
 
 
Figure 3.18.  The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM CeIV 
ammonium nitrate at pH 4.8 or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as 
calculated by choline concentrations. The graphs in column (a) are results at 37 °C and the 
graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage of 
hydrolysis calculated from the Amplex Red assay results of choline. Corresponding yield ratios 
are in Figure 3.16 (b). 
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     (a)                                (b) 
 
 
Figure 3.19.  The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM CeIV 
ammonium nitrate at pH 4.8 or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as 
calculated by inorganic phosphate concentrations. The graphs in column (a) are results at 37 °C 
and the graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage 
of hydrolysis calculated from the malachite green assay for phosphate.  
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     (a)                               (b) 
 
 
Figure 3.20.  The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM ZrCl4 at pH 4.8 
or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as calculated by total 
phosphocholine plus choline concentrations. The graphs in column (a) are results at 37 °C and 
the graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage of 
hydrolysis calculated from the Amplex Red assay results of phosphocholine and choline. 
Corresponding yield ratios are in Figure 3.15 (a). 
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   (a)                     (b) 
 
 
Figure 3.21.  The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM ZrCl4 at pH 4.8 
or pH 7 at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as calculated by choline concentrations. 
The graphs in column (a) are results at 37 °C and the graphs in column (b) are the results at 60 
°C. For (a) and (b), the y-axis is the percentage of hydrolysis calculated from the Amplex Red 
assay results of choline. Corresponding yield ratios are in Figure 3.16 (a). 
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    (a)        (b) 
 
 
Figure 3.22.  The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM ZrCl4 at pH 4.8 
or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as calculated by inorganic 
phosphate concentrations. The graphs in column (a) are results at 37 °C and the graphs in column 
(b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage of hydrolysis calculated 
from the malachite green assay for phosphate.  
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Table 3.6.  The percentage hydrolysis by total phosphocholine plus choline concentrations (or 
choline-only concentrations) for the reaction progress of the ZrIV metal-assisted hydrolysis of 
sphingomyelin with four timepoints. 
 
Metal 
ion 
Triton 
X-100 
(mM) 
Temp.
(°C) 
Time 
(h) 
Percentage Hydrolysis  
at pH 4.8 
 
Avg. ± SD %  
of total phosphocholine plus choline 
(Avg. ± SD  
of choline only) 
Percentage Hydrolysis  
at pH 7 
 
Avg. ± SD % 
of total phosphocholine plus choline 
(Avg. ± SD  
of choline only) 
ZrIV 0 37 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
   4 0.23 ≤ 0.04 
(0.05 ≤ 0.00) 
0.04 ≤ 0.05 
(-0.20 ≤ 0.00) 
   8 0.23 ≤ 0.11 
(-0.10 ≤ 0.00) 
0.10 ≤ 0.03 
(0.00 ≤ 0.00) 
   20 0.50 ≤ 0.21 
(-0.10 ≤ 0.00) 
0.23 ≤ 0.02 
(0.00 ≤ 0.00) 
  60 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
   4 0.71 ≤ 0.13 
(0.46 ≤ 0.01) 
0.87 ≤ 0.17 
(0.65 ≤ 0.14) 
   8 1.08 ≤ 0.07 
(0.54 ≤0.05) 
2.80 ≤ 0.02 
(2.05 ≤ 0.42) 
   20 4.50 ≤ 0.23 
(3.16 ≤ 0.54) 
5.60 ≤0.71 
(5.03 ≤1.2) 
 2 37 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.00 
(0.00 ≤0.00) 
   4 0.71 ≤ 0.06 
(0.46 ≤ 0.00) 
0.28 ≤ 0.05 
(0.25 ≤ 0.00) 
   8 1.07 ≤0.30 
(0.42 ≤ 0.03) 
0.65 ≤ 0.05 
(0.46 ≤ 0.02) 
   20 2.20 ≤ 0.40 
(1.55 ≤ 0.39) 
1.29 ≤ 0.22 
(0.76 ≤ 0.05) 
  60 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.00 
(0.00 ≤0.00) 
   4 10.4 ≤ 0.55 
(5.91 ≤ 0.12) 
6.07 ≤0.04 
(4.18 ≤ 0.80) 
   8 17.4 ≤ 2.1 
(12.1 ≤ 1.5) 
13.2 ≤ 1.1 
(8.62 ≤ 1.3) 
   20 44.3 ≤ 6.6 
(36.0 ≤ 7.6) 
33.6 ≤ 5.6 
(28.2 ≤ 6.7) 
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Continued Table 3.6.:  The percentage hydrolysis by total phosphocholine plus choline 
concentrations or choline-only concentrations for the reaction progress of the ZrIV metal-assisted 
hydrolysis of sphingomyelin with four timepoints. 
 
Metal 
ion 
Triton 
X-100 
(mM) 
Temp.
(°C) 
Time 
(h) 
Percentage Hydrolysis  
at pH 4.8 
 
Avg. ± SD % 
of total phosphocholine plus 
choline 
(Avg. ± SD  
of choline only) 
Percentage Hydrolysis  
at pH 7 
 
Avg. ± SD % 
of total phosphocholine plus choline 
(Avg. ± SD  
of choline only) 
ZrIV 16 37 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
   4 2.35 ≤ 0.34 
(1.53 ≤ 0.36) 
1.11 ≤ 0.09 
(0.53 ≤ 0.13) 
   8 5.00 ≤ 0.45 
(3.04 ≤ 0.36) 
1.49 ≤ 0.04 
(1.18 ≤ 0.12) 
   20 12.9 ≤ 1.2 
(8.30 ≤ 0.90) 
4.09 ≤ 0.27 
(3.02 ≤ 0.35) 
  60 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
   4 25.3 ≤ 0.92 
(15.8 ≤ 0.54) 
19.3 ≤ 0.6 
(14.5 ≤ 0.6) 
   8 41.3 ≤ 1.1 
(28.6 ≤ 1.3) 
38.3 ≤ 5.8 
(27.8 ≤ 3.8) 
   20 80.7 ≤7.4 
(62.6 ≤ 7.061) 
84.7 ≤ 6.0 
(72.1 ≤ 4.7) 
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Table 3.7.  The percentage hydrolysis by total phosphocholine plus choline concentrations or 
choline-only concentrations for the reaction progress of the CeIV metal-assisted hydrolysis of 
sphingomyelin with four timepoints. 
 
Metal Triton 
X-100 
(mM) 
Temp. 
(°C) 
Time 
(h) 
Percentage Hydrolysis at 
pH 4.8 
 
Avg. ± SD  
of total phosphocholine plus choline 
(Avg. ± SD  
of choline only) 
Percentage Hydrolysis at 
pH 7 
 
Avg. ± SD  
of total phosphocholine plus choline 
(Avg. ± SD  
of choline only) 
CeIV 0 37 0 0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
   4 4.88 ≤ 0.11 
(4.36 ≤ 0.55) 
5.04 ≤ 1.0 
(5.50 ≤ 1.3) 
   8 8.06 ≤ 1.8 
(5.08 ≤ 1.2) 
5.26 ≤ 0.34 
(4.71 ≤ 0.37) 
   20 17.0 ≤ 2.1 
(17.3 ≤ 1.6) 
14.18 ≤ 2.9 
(12.3 ≤ 3.0) 
  60 0 0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
   4 39.6 ≤ 4.2 
(36.7 ≤ 4.5) 
21.1 ≤ 3.4 
(20.5 ≤ 3.0) 
   8 53.9 ≤ 6.1 
(49.5 ≤ 9.0) 
34.0 ≤ 3.2 
(32.3 ≤ 2.0) 
   20 80.9 ≤ 2.5 
(77.6 ≤ 6.0) 
52.5 ≤ 7.6 
(49.6 ≤ 5.3) 
 2 37 0 0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
   4 9.75 ≤ 1.5 
(9.28 ≤ 1.2) 
13.0 ≤ 2.9 
(13.3 ≤ 2.8) 
   8 17.4 ≤ 0.32 
(14.3 ≤ 1.6) 
22.5 ≤ 1.1 
(20.7 ≤ 2.0) 
   20 31.2 ≤ 0.66 
(28.9 ≤ 2.0) 
30.1 ≤ 7.4 
(29.2 ≤ 6.0) 
  60 0 0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
0.00 ≤ 0.00 
(0.00 ≤ 0.00) 
   4 48.7 ≤ 7.6 
(45.6 ≤ 5.8) 
32.5 ≤ 0.14 
(31.8 ≤ 1.2) 
   8 69.3 ≤ 3.3 
(68.5 ≤ 3.1) 
47.1 ≤ 0.58 
(46.3 ≤ 0.03) 
   20 94.2 ≤ 14.1 
(91.6 ≤ 11.9) 
65.8 ≤ 0.63 
(65.2 ≤ 1.1) 
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Continued Table 3.7.:  The percentage hydrolysis by total phosphocholine plus choline 
concentrations or choline-only concentrations for the reaction progress of the CeIV metal-assisted 
hydrolysis of sphingomyelin with four timepoints. 
 
Metal Triton 
X-100 
(mM) 
Temp. 
(°C) 
Time 
(h) 
Percentage Hydrolysis at 
pH 4.8 
 
Avg. ± SD  
of total phosphocholine plus choline 
(Avg. ± SD  
of choline only) 
Percentage Hydrolysis at 
pH 7 
 
Avg. ± SD  
of total phosphocholine plus 
choline 
(Avg. ± SD  
of choline only) 
CeIV 16 37 0 0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
   4 19.3 ≤ 2.7 
(15.6 ≤ 0.90) 
20.2 ≤ 1.5 
(19.9 ≤ 4.4) 
   8 31.8 ≤ 4.4 
(25.5 ≤ 3.7) 
40.7 ≤ 3.78 
(36.9 ≤3.8) 
   20 48.2 ≤ 7.6 
(47.1 ≤ 3.9) 
53.3 ≤ 7.8 
(53.3 ≤ 9.4) 
  60 0 0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
0.00 ≤ 0.0 
(0.00 ≤ 0.0) 
   4 63.9 ≤ 9.2 
(60.5 ≤7.6) 
28.6 ≤ 1.9 
(28.3 ≤ 5.7) 
   8 79.5 ≤ 8.8 
(77.9 ≤ 11) 
55.7 ≤ 6.6 
(59.8 ≤ 0.22) 
   20 90.5 ≤ 16 
(91.2 ≤ 11) 
71.5 ≤ 13.0 
(67.8 ≤ 14) 
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Table 3.8.  The percentage hydrolysis by phosphate concentrations for the reaction progress of 
the ZrIV metal-assisted hydrolysis of sphingomyelin with four timepoints. 
 
Metal Triton 
X-100 
(mM) 
Temp. 
(°C) 
Time 
(h) 
Percentage Hydrolysis 
at pH 4.8 
Avg. ± SD % 
Percentage Hydrolysis at 
pH 7 
Avg. ± SD % 
ZrIV 0 37 0 0.00 ≤ 0.00 0.00 ≤ 0.00 
   4 0.12 ≤ 0.01 0.06 ≤ 0.00 
   8 0.17 ≤ 0.01 0.13 ≤ 0.01 
   20 0.19 ≤ 0.01 0.10 ≤ 0.01 
  60 0 0.00 ≤ 0.00 0.00 ≤ 0.00 
   4 0.43 ≤ 0.02 0.21 ≤ 0.01 
   8 0.23 ≤ 0.01 0.42 ≤ 0.02 
   20 0.51 ≤ 0.03 0.81 ≤ 0.04 
 2 37 0 0.00 ≤ 0.00 0.00 ≤ 0.00 
   4 0.11 ≤ 0.01 0.27 ≤ 0.01 
   8 0.24 ≤ 0.01 0.29 ≤ 0.01 
   20 0.38 ≤ 0.02 0.24 ≤ 0.01 
  60 0 0.00 ≤ 0.00 0.00 ≤ 0.00 
   4 0.65 ≤ 0.03 0.28 ≤ 0.01 
   8 0.91 ≤ 0.05 0.55 ≤ 0.03 
   20 3.44 ≤ 0.17 2.02 ≤ 0.10 
 16 37 0 0.00 ≤ 0.00 0.00 ≤ 0.00 
   4 0.38 ≤ 0.02 0.31 ≤ 0.02 
   8 0.55 ≤ 0.03 0.55 ≤ 0.03 
   20 0.78 ≤ 0.04 0.61 ≤ 0.03 
  60 0 0.00 ≤ 0.00 0.00 ≤ 0.00 
   4 1.77 ≤ 0.09 1.01 ≤ 0.05 
   8 2.95 ≤ 0.15 2.00 ≤ 0.10 
   20 8.54 ≤ 0.43 7.89 ≤ 0.39 
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Table 3.9.  The percentage hydrolysis by phosphate concentrations for the reaction progress of 
the CeIV metal-assisted hydrolysis of sphingomyelin with four timepoints. 
 
Metal Triton 
X-100 
(mM) 
Temp. 
(°C) 
Time 
(h) 
Percentage Hydrolysis 
at pH 4.8 
 
Avg. ± SD % 
Percentage Hydrolysis 
at pH 7 
 
Avg. ± SD % 
CeIV 0 37 0 0.00 ≤ 0.0 0.00 ≤ 0.0 
   4 0.07 ≤ 0.0 1.35 ≤ 0.21 
   8 0.24 ≤ 0.66 1.26 ≤ 0.23 
   20 5.84 ≤ 0.54 5.36 ≤ 0.86 
  60 0 0.00 ≤ 0.0 0.00 ≤ 0.0 
   4 14.1 ≤ 1.9 11.2 ≤ 2.0 
   8 21.1 ≤ 1.5 14.4 ≤ 0.55 
   20 37.6 ≤ 2.1 38.3 ≤ 1.8 
 2 37 0 0.00 ≤ 0.0 0.00 ≤ 0.00 
   4 1.22 ≤ 0.33 3.11 ≤ 0.77 
   8 3.35 ≤ 0.29 3.64 ≤ 0.01 
   20 7.18 ≤ 0.84 10.2 ≤ 1.0 
  60 0 0.00 ≤ 0.0 0.00 ≤ 0.0 
   4 16.5 ≤ 0.88 18.0 ≤ 1.3 
   8 36.3 ≤ 3.0 23.5 ≤ 0.45 
   20 96.2 ≤ 5.3 74.5 ≤ 11 
 16 37 0 0.00 ≤ 0.0 0.00 ≤ 0.00 
   4 4.85 ≤ 0.62 7.08 ≤ 0.87 
   8 9.21 ≤ 0.59 8.39 ≤ 0.70 
   20 19.6 ≤ 2.6 16.9 ≤ 3.5 
  60 0 0.00 ≤ 0.0 0.00 ≤ 0.0 
   4 33.5 ≤ 1.8 21.3 ≤ 1.5 
   8 45.9 ≤ 5.6 28.2 ≤ 0.15 
   20 60.4 ≤ 2.6 35.1 ≤ 0.28 
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Table 3.10.  Estimated half-lives (t1/2) calculated from ZrIV and CeIV hydrolysis of sphingomyelin 
at 60 °C or 37 °C from the total phosphocholine plus choline hydrolysis yield percentage or the 
choline-only yield percentage. “nd” signifies “not determined”. 
 
  
  
Estimated t1/2 (h) 
 
Metal Triton 
X-100 
(mM) 
Temperature Avg. pH Total phosphocholine 
plus choline 
 
Avg. ± SD 
Choline 
 
 
Avg. ± SD 
ZrIV 0 60 °C 4.84 300 ≤ 1 433 ≤ 1 
   7.03 200 ≤ 1 267 ≤ 1 
 2  4.89 24 ≤ 1 30 ≤ 1 
   7.06 33 ≤ 1 41 ≤ 1 
 16  4.89 8 ≤ 0.5 14 ≤ 1 
  
 7.07 7 ≤ 0.5 11 ≤ 0.3 
CeIV 0  4.72 9 ≤ 1 10 ≤ 0.2 
   6.95 19 ≤ 1 21 ≤ 0.3 
 2  4.86 5 ≤ 1 6 ≤ 0.1 
   7.01 14 ≤ 1 14 ≤ 0.2 
 16  4.75 6 ≤ 0.2 6 ≤ 0.2 
   7.02 11 ≤ 0.2 13 ≤ 0.2 
ZrIV 0 37 °C 4.89 3500≤ 4 nd 
   7.04 7000 ≤ 2 nd 
 2  4.90 800 ≤ 2 800 ≤ 1 
   
7.06 1200 ≤ 1 nd 
 16  4.90 100 ≤ 1 150 ≤ 1 
   7.06 350 ≤ 1 400 ≤ 1 
CeIV 0  4.78 80 ≤ 1 60≤ 1 
   7.02 80 ≤ 1 100 ≤ 1 
 2  4.80 40 ≤ 1 50 ≤ 1 
   7.04 50 ≤ 1 40 ≤ 1 
 16  4.86 26 ≤ 1 25 ≤ 1 
   
7.06 20 ≤ 1 20 ≤ 1 
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Figure 3.23.  MALDI mass spectra showing the ZrIV-assisted hydrolysis of phosphocholine 
with the increasing choline intensity at m/z 104.  Spectra represent  three different timepoints 
in the reaction at 0, 5, and 23 h. Samples prepared with 2 mM phosphocholine, 10 mM ZrCl4, 
20 mM TRIS, pH 4.8 were reacted at 60 °C, and then analyzed with MALDI-ToF 
instrumentation with DHB matrix in positive ion mode. 
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The zirconocene dichloride and non-metal experiments showed 0.05 to 0.12 pH drifts at 60 °C 
and -0.02 to 0.07 at 37 °C. The CeIV experiments showed pH drifts in the range of 0.08 to 0.10 at 
60 °C and -0.01 to 0.03 at 37 °C which is considerably less than the corollary pH 4.8 
experiments. The phosphocholine hydrolysis showed slight pH drifts at 0.05 pH units at 60 °C. 
The HEPES experiments demonstrate good pH control during the metal-assisted experiments.  
Method validation. 
Procedures using positive controls were performed to confirm that the experimental 
protocols are able to produce accurate results. The positive controls are compounds that are 
expected to give positive results because of their known reactivity with either the colorimetric 
reagents or the enzymatic reactions in the various assays. A known quantity of these compounds 
was used in similar hydrolysis reactions and/or assay quantification protocols as the hydrolysis 
samples, and  their observed results were recorded as recovery percentages that were used for 
statistical assessment and not correction factors since the recoveries are vial-specific. The 
Amplex Red assay quantification results of the positive controls of phosphocholine, choline, 
hydrogen peroxide, and the malachite green assay quantification results of inorganic phosphate 
levels are tabulated in Tables 3.12 and 3.13 for method validation. These results were evaluated 
to determine the validity and scientific significance of not only the established protocols of the 
Amplex Red assay and the malachite green assay, but the novel modified choline-only assay 
using the Amplex Red kit. The results for the 0 h and 20 h aliquots are shown separately to 
evaluate the effect of the experimental duration on the quantification. The positive controls were 
quantified by either the total phosphocholine plus choline assay where the enzyme mixture 
contained alkaline phosphatase or the choline-only assay where the enzyme mixture did not 
contain alkaline phosphatase.  
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The differences in metal, buffer, experimental time, and total phosphocholine plus 
choline yields vs. choline-only yields were noted. The recoveries of samples with zirconium(IV) 
metal were more accurate than the samples with cerium(IV) since the averages for zirconium(IV) 
were 98.4% (phosphocholine substrate, total phosphocholine plus choline analysis, 20 mM 
piperazine, 20h), 101.7% and 100.3% (choline substrate, total phosphocholine plus choline 
analysis, 20 mM piperazine, 0 and 20 h, respectively), 96.6% and 99.7% (choline substrate, 
choline-only analysis, 20 mM piperazine, 0 and 20 h, respectively). The recoveries for 
cerium(IV) metal were greater than the calculated value since the averages for cerium(IV) were 
114.6% and 112.0% (phosphocholine substrate, total phosphocholine plus choline analysis, 20 
mM piperazine, 0 and 20 h, respectively), 113.4% (phosphocholine substrate, total 
phosphocholine plus choline analysis, 20 mM HEPES, 20 h), 118.4% and 119.8% (choline 
substrate, total phosphocholine plus choline analysis, pH 4.8, 0 h and 20 h), 118.6% and 123.6 % 
(choline substrate, choline-only analysis, pH 4.8, 0 h and 20 h), and 123.4% and 127.4% (choline 
substrate, total phosphocholine and choline analysis, pH 7, 0 h and 20 h).  
The hydrogen peroxide positive controls provided by the manufacturer with the assay 
were prepared in pure reaction buffer without the presence of experimental metal and buffer 
concentrations. The recovery percentages for three different amounts averaged 69.5 ≤ 1.8 % of 
the calculated value. Since the peroxide positive controls were prepared from new vials and fresh 
dilutions to optimize the recoveries, the poor recovery results indicate that the hydrogen peroxide 
positive controls are unacceptable for method validation purposes. 
Table 3.13 shows the method validation statistics for the phosphate determinations from 
the malachite green assay. The expected phosphate concentration and the observed concentration 
calculated from the standard curves for each metal are shown with the recovery percentage. The 
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phosphate levels determined from the phosphocholine show 33.0% and 33.2% recoveries for 
ZrIV and CeIV-assisted hydrolysis of 1.116 mM phosphocholine in the presence of 10 mM metal, 
20 mM piperazine at 60 °C for 20 h which is substantially lower than the theoretical value.  The 
choline which contains no hydrolysable phosphate shows the expected 0.00% recovery for the 
CeIV-assisted hydrolysis of 1.49 mM choline in the presence of 10 mM CeIV and 20 mM 
piperazine at 60 °C for 20 h. The hydrolysis percentages calculated from the phosphate 
concentrations were compared to the corresponding hydrolysis percentages calculated from the 
Amplex Red assay. Two comparisons were taken from Table 3.3 and Table 3.4. For CeIV (2 
mM Triton X-100, pH 4.8), the hydrolysis percentages were 70.7 ≤ 7.1% and 81.2 ≤ 5.8% for 
phosphate and total phosphocholine plus choline assays, respectively, which is in good 
agreement.  However, for ZrIV (16 mM, pH 4.8), the hydrolysis percentages were 11.3 ≤ 2.2% 
and 73.0 ≤ 7.6% for phosphate and total phosphocholine plus choline assays, respectively, which 
is not in good agreement. The recoveries of the positive controls can not be strictly correlated to 
the hydrolysis percentages of the sphingomyelin by phosphate concentration because of more 
than one dephosphorylation pathway, e.g. phosphate from released phosphocholine or 
phosphoceramide. Also, the phosphate used for the preparation of the standard curves did not 
undergo the same 20 h heat treatment at 37 °C or 60 °C as that the hydrolysis samples or the 
method validation positive controls. 
Conclusions. 
The ability of a select group of metals to hydrolyze the phosphate ester bond of 
sphingomyelin has been demonstrated at two pH values which represent lysosomal and cytosolic 
pH conditions and two temperatures of 37 °C and 60 °C which are at or above the gel-liquid 
transition of sphingomyelin. Out of the 12 metals salts tested, the metals with the highest 
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reactivity are the tetravalent metals CeIV, ZrIV, and HfIV, and the divalent PdII.  This can be 
predicted by the tetravalent metals’ ability to substantially lower the pKa of water. A comparison 
of pH 4.8 and 7 yields at 60 °C show that hydrolysis by CeIV is strongly favored at pH 4.8 while 
ZrIV and HfIV do not show a strong pH preference according to phosphocholine and choline 
product yields.  However, the 37 °C data demonstrates that ZrIV hydrolysis of the phosphate ester 
bond is enhanced at lysosomal pH compared to cytosolic pH, while the CeIV hydrolysis is not 
enhanced at lysosomal pH. This reversal of trends at the two temperatures most likely reflects a 
temperature dependence of metal solubilities, kinetics, and liposomal structure. The hydrolytic 
yield differences are much lower at 37 ±C compared to 60 °C which reflects the effect of 
increasing temperature on reaction rates at 37 °C. Triton X-100 solubilization of sphingomyelin 
liposomes induces changes in the vesicle bilayer structure as evidenced by the turbidity and the 
altered hydrolytic yields for all metals. 
In the presence of 0, 2, and 16 mM Triton X-100 concentrations, according to the turbidity, 
sphingomyelin corresponds to distinctly different structures which are attributed to vesicles (0 
mM Triton X-100), mixed vesicle and mixed micelle (2 mM Triton X-100), and mixed micelle 
(16 mM Triton X-100) structures. Each of these sphingomyelin populations produced different 
metal-assisted hydrolytic yields. The additions of Triton X-100 and/or cholesterol had opposite 
effects on the pure sphingomyelin vesicles. The Triton X-100 incorporation increased hydrolytic 
yields possibly due to reduced Coloumbic repulsion of the charged headgroups due to Triton X-
100 interdigitation with concomitant micelle formation. Cholesterol incorporation decreased 
hydrolytic yields possibly due to closer packing of the fatty acid chains in the inner sections of 
the bilayers which causes a denser outer vesicle shell and less penetration of metal ions. 
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Table 3.11.  Summary of average pH and DpH values for all metal-assisted experiments. 
 
  60 °C 37 °C 
Experimental Conditions 
Triton 
X-100 
(mM) 
Avg pH ± SD DpH ± SD, n Avg pH ± SD DpH ± SD, n 
2mM sphingomyelin, 
10 mM ZrCl4, 
20 mM piperazine 
0 4.87 ≤ 0.03 0.03 ≤ 0.05, 28 4.88 ≤ 0.08 0.10 ≤ 0.09, 4 
2 4.86 ≤ 0.03 0.02 ≤ 0.03, 30 4.90 ≤ 0.04 0.04 ≤ 0.04, 4 
16 4.88 ≤ 0.03 -0.01 ≤  0.03, 30 4.94 ≤ 0.08 0.01 ≤ 0.02, 4 
2 mM sphingomyelin, 
10 mM HfCl4  
20 mM piperazine 
0 4.85 ≤ 0.01 0.01 ≤ 0.00, 10 na na 
2 4.83 ≤ 0.01 -0.02 ≤ 0.01, 10 na na 
16 4.88 ≤ 0.02 -0.01 ≤ 0.03, 10 na na 
2 mM sphingomyelin, 
10 mM CeIV ammonium nitrate, 
20 mM piperazine 
0 4.81 ≤ 0.19 0.48 ≤ 0.04, 25 4.71 ≤ 0.07 0.37 ≤ 0.13, 5 
2 4.73 ≤ 0.02 0.42 ≤ 0.04, 27 4.86 ≤ 0.10 0.29 ≤ 0.07, 6 
16 4.74 ≤ 0.02 0.42 ≤ 0.03, 27 4.91 ≤ 0.09 0.17 ≤ 0.08, 5 
2 mM sphingomyelin, 
No metal, 
20 mM piperazine 
0 4.92 ≤ 0.03 -0.09 ≤ 0.09, 9 4.95 ≤ 0.16 -0.03 ≤ 0.13, 4 
2 4.91 ≤ 0.02 -0.06 ≤ 0.08, 9 4.93 ≤ 0.09 -0.05 ≤ 0.06, 4 
16 4.92 ≤ 0.05 -0.12 ≤ 0.06, 17 4.89 ≤ 0.13 -0.09 ≤ 0.14, 4 
1.116 mM phosphocholine, 
10 mM CeIV ammonium nitrate, 
20 mM piperazine 
0 4.69 ≤ 0.06 0.53 ≤ 0.07, 18 na na 
2 na na na na 
16 na na na na 
2 mM sphingomyelin, 
10 mM zirconocene dichloride, 
20 mM piperazine 
0 4.86 ≤ 0.12 0.10 ≤ 0.10, 7 4.93 ≤ 0.06 -0.01 ≤ 0.08, 5 
2 4.88 ≤ 0.09 0.07 ≤ 0.08, 9 4.95 ≤ 0.04 0.03 ≤ 0.04, 6 
16 4.94 ≤ 0.08 0.10 ≤ 0.08, 9 5.01 ≤ 0.05 0.04 ≤ 0.05, 4 
      
2 mM sphingomyelin, 
10 mM ZrCl4, 
20 mM HEPES 
0 7.05 ≤ 0.02 0.02 ≤ 0.01, 26 7.02 ≤ 0.05 0.03 ≤ 0.07, 5 
2 7.05 ≤ 0.01 0.01 ≤ 0.01, 28 7.07 ≤ 0.04 -0.05 ≤ 0.04, 5 
16 7.06 ≤ 0.03 -0.03 ≤ 0.03, 28 7.05 ≤ 0.07 -0.05 ≤ 0.09, 5 
2 mM sphingomyelin, 
10 mM HfCl4 
20 mM HEPES 
0 7.10 ≤ 0.01 0.02 ≤ 0.01, 10 na na 
2 7.07 ≤ 0.00 0.00 ≤ 0.00, 9 na na 
16 7.10 ≤ 0.01 -0.03 ≤ 0.02, 10 na na 
2 mM sphingomyelin, 
10 mM CeIV ammonium nitrate, 
20 mM HEPES 
0 7.00 ≤ 0.05 0.10 ≤ 0.04, 24 7.05 ≤ 0.06 0.03 ≤ 0.11, 5 
2 7.02 ≤ 0.03 0.10 ≤ 0.04, 26 7.08 ≤ 0.01 0.01 ≤ 0.08, 5 
16 7.03 ≤ 0.01 0.08 ≤ 0.04, 26 7.08 ≤ 0.12 -0.01 ≤ 0.09, 5 
2 mM sphingomyelin, 
No metal, 
20 mM HEPES 
0 7.08 ≤ 0.14 0.12 ≤ 0.01, 9 6.99 ≤ 0.10 0.06 ≤ 0.24, 4 
2 7.16 ≤ 0.12 0.07 ≤ 0.11, 10 7.05 ≤ 0.08 0.00 ≤ 0.1, 5 
16 7.07 ≤ 0.12 0.05 ≤ 0.10, 16 7.01 ≤ 0.08 -0.02 ≤ 0.09, 4 
1.116 mM phosphocholine, 
10 mM CeIV ammonium nitrate, 
20 mM HEPES 
0 7.08 ≤ 0.08 0.05 ≤ 0.04, 14 na na 
2 na na na na 
16 na na na na 
2 mM sphingomyelin, 
10 mM zirconocene dichloride, 
20 mM HEPES 
0 7.03 ≤ 0.06 0.08 ≤ 0.14, 6 7.04 ≤ 0.05 0.07 ≤ 0.12, 5 
2 6.98 ≤ 0.07 0.06 ≤ 0.09, 9 7.01 ≤ 0.07 0.05 ≤ 0.12, 6 
16 6.99 ≤ 0.06 0.06 ≤ 0.09, 7 7.01 ≤ 0.11 0.05 ≤ 0.09, 4 
∆pH = initial reaction pH at t = 0 h minus final reaction pH at t = 20 h; 
na = not available; n = number of trials 
123 
 
Table 3.12.  Summary of the positive control results used in the Amplex® Red assay method validation.c 
 
Positive 
Control 
Sample  Parameters Total phosphocholine 
and cholinea 
Cholineb 
t = 0 h t = 20 h t = 0 h t = 20 h 
Phosphocholine 1.116 mM phosphocholine, 
10 mM ZrCl4,  
20 mM piperazine, pH 4.8, 
60 °C, 20 h 
Calculated concentration (mM) 
Observed concentration (mM) ≤ SD 
n 
Recovery % 
1.12 mM 
0.980 ≤ 0.11 
3 
87.8% 
1.12 mM 
1.10 ≤ 0.29                                              
4 
98.4 % 
0 mM 
0.039 ≤ 0.61
3 
3.50 % 
1.116 mM 
0.888  
2 
79.6 % 
Phosphocholine 1.116 mM phosphocholine, 
10 mM CeIV ammonium 
nitrate,  
20 mM piperazine, pH 4.8, 
60 °C, 20 h 
Calculated Concentration (mM) 
Observed concentration (mM) ≤ SD 
n 
Recovery % 
1.12 mM 
1.28 ≤ 0.23 
5 
114.6 % 
1.12 mM   
1.25 ≤ 0.25 
5 
112.0 % 
1.12 mM  
0.213 ≤ 0.04                           
3                                                  
19.09 %                                  
1.12 mM  
1.19 ≤ 0.26 
4
106.5 %
Phosphocholine 1.116 mM phosphocholine, 
10 mM CeIV ammonium 
nitrate,  
20 mM HEPES, pH 7, 60 
°C, 20 h 
Calculated Concentration (mM) 
Observed concentration (mM) ≤ SD  
n 
Recovery % 
1.12 mM 
1.15 ≤ 0.16 
4 
103.4 % 
1.12 mM   
1.26 ≤ 0.18 
4 
113.4 % 
1.12 mM  
0.290 ≤ 0.13                           
3                                                  
26.0 %                                  
1.12 mM  
1.17 ≤ 0.06 
3
105.0 %
Choline 1.116 mM phosphocholine, 
10 mM ZrCl4,  
20 mM piperazine, pH 4.8, 
60 °C, 20 h 
Calculated Concentration (mM) 
Observed concentration (mM) ≤ SD 
n 
Recovery % 
1.49 mM 
1.52  
2 
101.7 % 
1.49 mM 
1.49  
2 
100.3 % 
1.49 mM 
1.44 ≤ 0.08 
3 
96.6 % 
1.49 mM 
1.49 ≤ 0.09 
4 
99.7 % 
Choline 1.116 mM phosphocholine, 
10 mM CeIV ammonium 
nitrate,  
20 mM piperazine, pH 4.8, 
60 °C, 20 h 
Calculated Concentration (mM) 
Observed concentration (mM) ≤ SD  
n 
Recovery % 
1.49 mM 
1.76 ≤ 0.17 
5 
118.4 % 
1.49 mM 
1.79 ≤ 0.20 
5 
119.8 % 
1.49 mM 
1.77 ≤ 0.31 
4 
118.6 % 
1.49 mM 
1.84 ≤ 0.30 
4 
123.6 % 
a
 The total phosphocholine and choline amount is calculated from the Amplex Red assay where alkaline phosphatase enzyme was included in the 
reactive mix. Results include the phosphocholine and choline substrate present in the hydrolysis reaction. Metals included ZrCl4 or cerium(IV) ammonium 
nitrate. Buffers included either piperazine, pH 4.8, or HEPES, pH 7.0. 
b
 The choline amount is the amount calculated from the Amplex Red assay where alkaline phosphatase enzyme was omitted in the reactive mix. Results 
include only the choline substrate present in the hydrolysis reaction. 
c
 “na” = not available, n = number of samples 
d
 The hydrogen peroxide samples were prepared immediately prior to the assay preparation and not a metal-assisted hydrolysis reaction. 
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Continued Table 3.12.:  Summary of the positive control results used in the Amplex® Red assay method validation.c 
 
Positive 
Control 
Sample  Parameters Total phosphocholine 
and cholinea 
Cholineb 
t = 0 h t = 20 h t = 0 h t = 20 h 
Choline 1.116 mM phosphocholine, 
10 mM CeIV ammonium 
nitrate, 20 mM HEPES, pH 
7,  60 °C, 20 h 
Calculated Concentration (mM) 
Observed concentration (mM) ≤ SD 
n 
Recovery % 
1.49 mM 
1.84 ≤ 0.12 
3 
123.4 % 
1.49 mM 
1.90 ≤ 0.23 
3 
127.4 % 
1.49 mM 
1.68 
2 
112.6 % 
1.49 mM 
1.76  
2 
117.8 % 
H2O2 Reaction bufferd 
(Tris, MgCl), 
37 °C 
Calculated Concentration (mM) 
Observed concentration (mM)  
n 
Recovery % 
0.022 mM  
0.015  
2 
68.2 % 
na na na 
H2O2 Reaction bufferd 
(Tris, MgCl) 
37 °C 
Calculated Concentration (mM) 
Observed concentration (mM)  
n 
Recovery % 
0.044 mM 
0.031  
2 
71.6 % 
na na na 
H2O2 Reaction bufferd 
(Tris, MgCl) 
37 °C 
Calculated Concentration (mM) 
Observed concentration (mM)  
n 
Recovery % 
na na 0.066 mM 
0.045  
2 
68.8 % 
na 
a
 The total phosphocholine and choline amount is calculated from the Amplex Red assay where alkaline phosphatase enzyme was included 
in the reactive mix. Results include the phosphocholine and choline substrate present in the hydrolysis reaction. Metals included ZrCl4 or 
cerium(IV) ammonium nitrate. Buffers included either piperazine, pH 4.8, or HEPES, pH 7.0. 
b
 The choline amount is the amount calculated from the Amplex Red assay where alkaline phosphatase enzyme was omitted in the reactive 
mix. Results include only the choline substrate present in the hydrolysis reaction. 
c
 “na” = not available, n = number of samples 
d
 The hydrogen peroxide samples were prepared immediately prior to the assay preparation and not a metal-assisted hydrolysis reaction. 
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Table  3.13.  Summary of the positive control results used in the malachite green assay method validation. 
 
Positive Control Sample Description Parameter Inorganic Phosphate 
t = 20 h - 0 h  
Phosphocholine 1.116 mM phosphocholine, 
10 mM ZrCl4, 20 mM 
piperazine, pH 4.8, 60 °C, 20 h 
Calculated concentration (µM) 
Observed concentration (µM) ≤ SD 
n 
Recovery % 
1120 uM  
370 uM  
2 
33.0 % 
 
Phosphocholine 1.116 mM phosphocholine, 
10 mM metal CeIV ammonium 
nitrate, 20 mM piperazine, pH 
4.8,  60 °C, 20 h 
Calculated concentration (µM) 
Observed concentration (µM) ≤ SD 
n 
Recovery % 
1120 uM  
372 uM ≤ 117 
4 
33.2 % 
 
Phosphocholine 1.116 mM phosphocholine, 
10 mM metal CeIV ammonium 
nitrate, 20 mM HEPES, pH 7, 60 
°C, 20 h 
Calculated concentration (µM) 
Observed concentration (µM) ≤ SD 
n 
Recovery % 
1120 uM  
447 uM ≤ 307 
3 
39.9 % 
 
Choline 1.490 mM choline, 
10 mM metal (CeIV ammonium 
nitrate), 20 mM piperazine, pH 
4.8, 60 °C, 20 h 
Calculated Concentration (µM) 
Observed concentration (µM) ≤ SD 
n 
Recovery % 
0 uM 
-9.04 uM  
2 
< 0.00 % 
 
Choline 1.490 mM choline, 
10 mM metal (CeIV ammonium 
nitrate), 20 mM HEPES, pH 7, 
60 °C, 20 h 
Calculated Concentration (µM) 
Observed concentration (µM) ≤ SD 
n 
Recovery % 
0 uM 
16.02 uM  
2 
>0.00% 
 
n = number of trials
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The evaluation of ZrIV-assisted metal hydrolysis of sphingomyelin as a possible therapeutic 
reagent in Niemann-Pick diseases Type A and B is confirmed because the hydrolysis is increased 
at lysosomal pH at physiological temperatures of 37 °C.  The cellular toxicity of metals which 
are used as therapeutic agents must be taken into account, and zirconium(IV) metal is non-toxic 
while cerium(IV) is toxic whose effects including liver damage may be better understood in 
terms of cerium(IV)’s ability to hydrolyze the phosphate ester bond in sphingomyelin. 
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CHAPTER IV    CONCLUSIONS. 
 
Peptide hydrolysis. 
 
We have described in the first chapter the potential uses for metal-assisted hydrolysis of 
the peptide bond or the phosphate ester bond for potential therapeutic and proteolytic use. In the 
second chapter, we have described the unique application of ZrIV-assisted hydrolysis of the 
peptide bond of a biologically-active protein using a metal-azacrown ether complex. By using 
HPLC-ESI-MS and MS/MS, and MALDI-TOF MS, we have demonstrated that ZrIV/4, 13-diaza-
18-crown-6 facilitates hydrolysis of the 30-mer oligopeptides oxidized bovine insulin chain B at 
pH 7.0 and 60 °C. The ZrIV-assisted hydrolysis of insulin chain B demonstrated that not only 
does the ZrIV have amino acid side chain specificity, but that it hydrolyzes in good yields. Using 
the extensive characterization of the hydrolysis products by Findpept software and MS/MS mass 
spectral techniques, we were able to discover that the ZrIV in the presence of the azacrown ether 
hydrolyzes not only at oxophilic, negatively-charged amino acids as predicted by earlier 
dipeptide work, but also possesses an unprecedented specificity toward cysteine sulfonic acid 
which is a distinctive marker for protein oxidative stress. This may be a useful metalloprotease 
for proteolytic studies which focus on the effect of oxidative stress on proteins.  
 In our analysis of the hydrolysis products, apparent major levels of cleavage were 
produced at Gly8-Ser9, Gly20-Glu21, Ser9-His10, Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20 
sequences which indicates three hydrolytic specificities, namely, cysteine sulfonic acids, 
negatively-charged, sequential Gly-Glu, and a Gly-Ser-His motif which contains an oxygen-
containing sidechain. Given the association of cysteine sulfonic acids in proteins that have 
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undergone oxidative stress such as those found in amyloid fibril formation, Parkinson’s disease, 
and other physiological processes, the therapeutic potential in the hydrolysis of these 
irreversibly-oxidized amino acids to prevent possible misfolding is promising.Two minor side 
reactions were also characterized in order to monitor any peptide product modifications.  It was 
found that the ZrIV/4,13-diaza-18-crown-6 complex promotes lactamization of the N-terminal 
Glu21 and deamidation of Asn3 and Gln4.  
Phospholipid hydrolysis. 
 The development of ZrIV and other non-toxic metal complexes for therapeutic treatment 
of patients with Niemann-Pick Disease and other lysosomal storage disorders is a very novel, 
promising area of research. We first analyzed a group of metals, described in Chapter III, which 
included transition metals and lanthanides with demonstrated ability to hydrolyze the phosphate 
ester bond in synthetic compounds. While the ZrIV does not have significant cellular toxicity and 
has potential therapeutic use, the toxic effects of CeIV through phosphate ester hydrolytic 
pathways may be elucidated through this study. Two different assays were chosen for 
quantification of yields including the malachite green assay which quantitates inorganic 
phosphate and the Amplex-Red assay which measures the total phosphocholine plus choline 
yields. The novel adaptation of this Amplex-Red assay by inclusion of a choline-specific 
enzymatic reaction using similar reagents with selective omission of the alkaline phosphatase 
enzyme produced corollary results that allowed quantification and comparison of both the 
phosphocholine and the choline yields. This differentiation between phosphocholine and choline 
yields allows direct assessment of the regioselectivity of the metal-assisted hydrolysis of the 
phosphate ester bond of sphingomyelin in order to compare with the physiological enzymatic 
hydrolysis by acid sphingomyelinase in the lysosomes which yields exclusively phosphocholine 
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product plus a ceramide that proceeds as a second messenger to downstream signal transduction 
cascades. The data show that tetravalent metals ZrIV, CeIV, and HfIV and the divalent PdII 
hydrolyze the phosphate ester bond in sphingomyelin in high yields. The solubilization of pure 
sphingomyelin vesicles to mixed micelles and/or pure micelles by the addition of Triton X-100 
surfactant increased hydrolysis rates. Estimated half-lives of CeIV and ZrIV for pure 
sphingomyelin liposomes with Triton X-100 solubilization at 60 °C are 5.06 h and 6.50 h, 
respectively. All hydrolysis experiments were run in parallel at two pH values which represent 
lysosomal pH 4.8 and cytosolic pH 7 in order to assess the increase in hydrolysis of the 
phosphate ester bond, and thus enzymatic mimicry, at lysosomal pH relative to cytosolic pH. We 
have shown that ZrIV-assisted hydrolysis of pure sphingomyelin liposomes at 37 °C is 
significantly enhanced at pH 4.8 compared to pH 7 in micellar form.  Experiments with 
cholesterol effects on sphingomyelin liposomes demonstrate that the dense packing effects of 
cholesterol decrease the hydrolysis rates. Overall, we have demonstrated metal-assisted 
hydrolysis of a major, physiological phospholipid to yield non-cytotoxic products of 
phosphocholine and choline. 
